Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth Medicare PPO prior auth & coverage | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAmeriHealthPolicy N/A

    AmeriHealth Medicare PPO pharmacy prior authorization and utilization management criteria (partial)

    Customize your policy alerts

    Sign up for all AmeriHealth policy alerts

    Know when AmeriHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Portion of the AmeriHealth Medicare PPO pharmacy policy listing drugs subject to utilization management (prior authorization, step therapy, quantity limits) and providing criteria summaries for selected products.

    Policy Summary
    PayerAmeriHealth
    PolicyMedicare PPO pharmacy prior authorization and utilization management criteria (partial)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date10/15/2025
    Next Review DateN/A
    Key ActionObtain prior authorization and provide required clinical documentation (diagnosis, prior therapies, specialist consultation) when a drug is marked PA.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipledrugs with PA/UM rules in excerpt
    PA, ST, QLutilization management types
    12 monthscommon coverage duration
    Yesspecialist prescribing required
    age / prescriber / durationcommon criteria elements

    Coverage Criteria and Indication-Specific Requirements

    PAH initial and continuation

    Pulmonary arterial hypertension (PAH) and related agents — Covered when ALL of the following are met

    PAH initial criteria: (1) Documentation of a diagnosis of pulmonary arterial hypertension (PAH) WHO Group with NYHA Functional Class II–IV; (2) Diagnosis confirmed by right‑heart catheterization (or echocardiography when catheterization not available) with hemodynamic documentation including mean pulmonary arterial pressure > 20 mm Hg, pulmonary vascular resistance (PVR) > 2.0 Wood Units, and pulmonary capillary wedge pressure (PCWP) or left ventricular end‑diastolic pressure (LVEDP) ≤ 15 mm Hg; (3) Prescribed by or in consultation with a cardiologist or pulmonologist; (4) For some agents, documentation of inadequate response or intolerance to prior PAH‑specific classes as specified by the product-specific criteria.mean PAP >20 mm Hg; PVR >2.0 WU; PCWP/LVEDP ≤15 mm Hg

    Initial coverage typically 6 months; reauthorization 12 months contingent on specialist documentation of stabilization or improvement.

    MDD (AUVELITY)

    Major depressive disorder (AUVELITY) — Covered when ALL of the following are met

    Policy Summary
    PayerAmeriHealth
    PolicyMedicare PPO pharmacy prior authorization and utilization management criteria (partial)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date10/15/2025
    Next Review DateN/A
    Key ActionObtain prior authorization and provide required clinical documentation (diagnosis, prior therapies, specialist consultation) when a drug is marked PA.
    SourceLink
    On This Page
    Coverage Criteria and Indication-Specific RequirementsInitial Authorization / Initiation RequirementsReauthorization and Continuation RequirementsStep Therapy Requirements and Prior-Therapy TrialsPrior Authorization, Documentation & Denial Risk HighlightsCodes, Clinical Thresholds and Key ValuesSite-of-Care and Initiation Setting NotesBackground and ScopeDefinitions and Diagnostic Criteria
    MDD initial criteria: (1) Diagnosis of major depressive disorder (MDD); (2) Documentation of inadequate response or intolerance to two formulary antidepressants indicated for MDD (examples include bupropion, venlafaxine extended‑release, sertraline); (3) Prescriber documentation consistent with product labeling.

    Coverage duration: indefinite; continuation requires documentation of clinical benefit when requested for reauthorization.

    Cystic fibrosis (CAYSTON)

    Cystic fibrosis inhaled aztreonam (CAYSTON) — Covered when ALL of the following are met

    CF initial criteria: (1) Diagnosis of cystic fibrosis; (2) Evidence of Pseudomonas aeruginosa in respiratory cultures; (3) Microbiology demonstrating P. aeruginosa susceptibility to aztreonam; (4) Baseline FEV1 between 25% and 75% of predicted; (5) Member not colonized with Burkholderia cepacia.FEV1 25%–75% predicted

    Prescribed by or in consultation with a pulmonologist, infectious disease specialist, or CF care center specialist; coverage through remainder of contract year; reauthorization requires ongoing evidence of infection and clinical improvement (eg, improved FEV1).

    Biologics prior therapy requirements

    Biologic therapies (e.g., CIMZIA) for inflammatory conditions — Covered when ALL of the following are met

    Biologic prior therapy requirements: (1) Diagnosis of the specified inflammatory condition (eg, RA, PsA, PsO, AS, CD, UC) consistent with product‑specific indication; (2) Documentation of inadequate response or intolerance to the specified number and types of prior agents (commonly two prior biologic or targeted therapies or required DMARD trials as listed per indication) unless documentation shows a trial is inappropriate; (3) Prescribed by or in consultation with the appropriate specialist for the condition.

    Coverage duration typically 12 months; reauthorization generally requires documentation of positive clinical response.

    HAE prophylaxis

    Hereditary angioedema prophylaxis (CINRYZE) — Covered when ALL of the following are met

    HAE prophylaxis: (1) Diagnosis of hereditary angioedema (HAE); (2) Use of the requested product is for prophylaxis of HAE attacks; (3) Requested prophylactic product will not be used in combination with other prophylactic HAE products.

    Prescribed by or in consultation with an allergist, immunologist, or pulmonologist; coverage duration 12 months; reauthorization requires documentation of clinical benefit.

    Rinvoq — Crohn's Disease initial criteria

    Rinvoq — Crohn's Disease (Initial): Covered when ALL of the following are met

    Rinvoq for moderate to severe Crohn's Disease: (1) Diagnosis of moderately to severely active Crohn's disease; (2) Inadequate response or intolerance to two of the following: adalimumab, ustekinumab, risankizumab, or upadacitinib (Rinvoq) OR documentation that trials are inappropriate; (3) Prescribed by or in consultation with a gastroenterologist.

    Coverage duration: 12 months.

    nr-axSpA initial criteria

    Non-Radiographic Axial Spondyloarthritis (nr-axSpA) (Initial): Covered when ALL of the following are met

    nr-axSpA initial: (1) Diagnosis of non‑radiographic axial spondyloarthritis (nr‑axSpA); (2) Inadequate response or intolerance to Rinvoq OR Cosentyx OR documentation that such a trial is inappropriate; (3) Inadequate response or intolerance to at least one NSAID (eg, ibuprofen, meloxicam, naproxen).

    Prescriber specialty as specified in product criteria; reauthorization requires demonstration of clinical benefit.

    Entyvio initial criteria

    Entyvio — Ulcerative Colitis / Crohn's Disease initial criteria: Covered when ONE of the following pathways is met

    Entyvio UC/CD initial: Pathway A: Inadequate response or intolerance to two of the listed agents (eg, adalimumab, ustekinumab, upadacitinib, tofacitinib, risankizumab) OR documentation that trials are inappropriate; Pathway B: Use as maintenance following IV induction with Entyvio (two IV doses) or member is established on Entyvio IV.

    Prescribed by or in consultation with a gastroenterologist; coverage duration 12 months; reauth requires documented positive clinical response.

    Enbrel initial criteria

    Enbrel — Rheumatologic and dermatologic indications (Initial): Covered when ALL of the following are met

    Enbrel initial: (1) Indication‑specific diagnosis (eg, moderate to severe RA, PsA, PJIA, PsO, AS); (2) Inadequate response or intolerance to specified conventional DMARD(s) (eg, methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine) as required by the indication; (3) Prescribed by or in consultation with the appropriate specialist (rheumatologist or dermatologist).

    Concurrent biologic DMARD therapy is excluded; coverage duration typically 12 months; reauthorization requires evidence of positive clinical response.

    Dalfampridine initial criteria

    Dalfampridine (MS) initial criteria: Covered when ALL of the following are met

    Dalfampridine for MS: (1) Diagnosis of multiple sclerosis with documented difficulty walking; (2) Expanded Disability Status Scale (EDSS) ≤ 7 OR documentation that member is not restricted to a wheelchair if EDSS not measured; (3) No history of seizure and adequate renal function (CrCl > 50 mL/min).CrCl > 50 mL/min

    Prescribed by or in consultation with a neurologist; coverage through remainder of contract year; reauthorization requires documented improvement in walking speed.

    Epidiolex initial criteria

    Epidiolex (DS, LGS, TSC) initial criteria: Covered when ALL of the following are met

    Epidiolex indications: (1) Diagnosis of Dravet syndrome (DS), Lennox‑Gastaut syndrome (LGS), or tuberous sclerosis complex (TSC) as specified; (2) Inadequate response or intolerance to at least one specified anticonvulsant (eg, clobazam, valproic acid, topiramate) as applicable; (3) Baseline laboratory evaluation including CBC, serum transaminases, and total bilirubin prior to initiation; (4) Prescribed by or in consultation with a neurologist.

    Coverage duration indefinite; reauthorization allowed for continuation with demonstrated benefit.

    Sodium phenylbutyrate initial criteria

    Sodium phenylbutyrate (UCD) initial criteria: Covered when ALL of the following are met

    Sodium phenylbutyrate for UCD: (1) Diagnosis of a urea cycle disorder (UCD) involving deficiencies of CPS, OTC, or ASS confirmed by enzymatic, biochemical, or genetic testing; (2) Inadequate response to dietary protein restriction or amino acid supplementation; (3) Prescribed by or in consultation with a metabolic disorders specialist.

    Initial coverage 6 months; reauthorization 12 months requiring documentation of positive clinical response (eg, plasma ammonia or amino acid levels) and concomitant dietary management.

    Urea Cycle Disorder

    Urea Cycle Disorder (UCD) — Covered when ALL of the following are met

    UCD initial criteria: (1) Diagnosis of a urea cycle disorder involving deficiencies of CPS, OTC, or AAS confirmed by enzymatic, biochemical, or genetic testing; (2) Inadequate response to dietary protein restriction or amino acid supplementation.

    Initial coverage 6 months; reauthorization 12 months with documentation of clinical response and continued dietary management.

    Growth Hormone Products

    Growth hormone therapies — Covered when criteria specific to each indication are met

    Eligible indications for GH therapy: One of the following indications must be met: growth hormone deficiency confirmed by height/growth velocity/bone age and abnormal provocative testing; small for gestational age with failure of catch‑up growth by age 2–4 years; growth failure with chronic kidney disease; Noonan syndrome, Prader‑Willi syndrome, Turner syndrome or SHOX deficiency; adult growth hormone deficiency; idiopathic short stature (ISS) with height SDS ≤ -2.25.Height SDS ≤ -2.25 for ISS

    Prescribed by or in consultation with an endocrinologist; initial and continuation coverage typically 12 months with annual re‑evaluation and evidence of response (eg, increased growth velocity).

    TOBI PODHALER (tobramycin inhalation)

    TOBI PODHALER — Covered when ALL of the following are met

    TOBI PODHALER initial criteria: (1) Diagnosis of cystic fibrosis; (2) Evidence of Pseudomonas aeruginosa in the lungs; (3) Baseline FEV1 between 25% and 75% of predicted; (4) Member not colonized with Burkholderia cepacia.FEV1 25%–75% predicted

    Prescribed by or in consultation with a pulmonologist, infectious disease specialist, or CF care center specialist; coverage through remainder of contract year; reauth requires evidence of infection control and clinical improvement.

    Immune Globulin (GAMUNEX-C) Coverage

    Immune globulin (e.g., GAMUNEX-C) — Covered when indication-specific criteria are met

    IG indications: Multiple indication‑specific criteria qualify for IV/SC immune globulin, including autoimmune blistering diseases, acute and chronic ITP with defined platelet thresholds and prior therapy requirements, hematopoietic stem cell transplant with low IgG, select transplant/infectious indications, CIDP, dermatomyositis/polymyositis refractory to steroids, Guillain‑Barré with functional impairment, and others as listed in product criteria.Examples: platelet count <20,000/µL for certain ITP scenarios; IgG thresholds (≤600 mg/dL or ≤400 mg/dL) in select contexts.

    Coverage duration often 6 months for initial authorization; continuation requires documentation of clinical improvement and adherence to indication‑specific monitoring.

    Biologics (e.g., ILUMYA, KEVZARA, KINERET, RASUVO)

    Biologics for rheumatologic and dermatologic conditions — Covered when ALL of the following are met

    Biologic initial criteria: (1) Diagnosis of the indicated rheumatologic or dermatologic condition (eg, RA, PsA, PsO, PJIA); (2) Inadequate response or intolerance to the specified prior therapies (commonly two DMARDs or biologics, or methotrexate where required) OR documentation that trials are inappropriate; (3) Prescribed by or in consultation with the appropriate specialist (eg, rheumatologist or dermatologist).

    Concurrent biologic DMARD therapy is excluded; initial coverage commonly 12 months; reauthorization requires documented positive clinical response.

    High Dose Opioid Continuation

    High-dose opioid therapy — Continued coverage only when criteria met

    Continuing high-dose opioid therapy: For continuation of high‑dose opioid therapy (morphine equivalent dose ≥ 90 mg/day): ONE of the following must apply: (A) pain associated with cancer; OR (B) chronic non‑cancer pain and ALL of the following: (a) pain reassessed within the last 6 months; (b) clinically meaningful improvement in pain and function that outweighs safety risks; (c) member is not being treated for substance abuse.MED ≥ 90 mg/day

    Coverage through remainder of contract year; subject to additional clinical review for ESRD where applicable.

    JYNARQUE (tolvaptan)

    JYNARQUE (tolvaptan) — Covered when ALL are met

    JYNARQUE initial criteria: (1) Diagnosis of autosomal dominant polycystic kidney disease (ADPKD) at risk for rapidly progressing kidney disease; (2) Baseline liver transaminases and total bilirubin obtained prior to initiation of therapy.

    Initial coverage 3 months; reauthorization 12 months requiring evidence of slowed decline in kidney function or improvement in kidney pain and liver tests within specified limits; prescribed by or in consultation with a nephrologist or transplant specialist.

    Kineret - Initial RA criteria

    Kineret (anakinra) coverage criteria (examples present in excerpt):

    RA initial: (1) Diagnosis of rheumatoid arthritis; (2) Inadequate response or intolerance to TWO of the following: adalimumab, etanercept (Enbrel), Rinvoq, tofacitinib/Xeljanz, Orencia OR documentation that trials are inappropriate.

    Prescribed by or in consultation with a rheumatologist; coverage duration 12 months; reauthorization requires documentation of positive clinical response. Concurrent biologic DMARD therapy is excluded.

    Livtencity - CMV criteria

    Livtencity (ganciclovir prodrug) coverage criteria (CMV):

    CMV initial: (1) Diagnosis of cytomegalovirus (CMV) infection or disease; (2) Recipient of hematopoietic stem cell transplant or solid organ transplant; (3) Inadequate response to or intolerance of at least 2 weeks of one prior appropriate therapy (eg, oral valganciclovir) at the indicated dose; (4) For pediatric patients (≥12 years), weight ≥ 35 kg.weight ≥ 35 kg for pediatric ≥12 yrs

    Prescribed by or in consultation with transplant, infectious disease, or oncology specialist; coverage duration 8 weeks.

    Nexletol/Nexlizet - Initial criteria

    Nexletol/Nexlizet coverage criteria (lipid disorders):

    Initial HeFH/Primary hyperlipidemia: (1) Diagnosis of heterozygous familial hypercholesterolemia (HeFH) or primary hyperlipidemia; (2) LDL‑C at or above specified threshold after at least an 8‑week trial of a moderate‑intensity statin at maximally tolerated dose OR documented statin intolerance; (3) At least 8–12 weeks of ezetimibe therapy as adjunct to statin where required or documentation of contraindication/intolerance to ezetimibe; (4) Additional LDL and CVD risk criteria apply per product specifics.LDL‑C ≥70 mg/dL after ≥8‑week statin trial; also >=55 mg/dL with ASCVD or >=100 mg/dL without ASCVD per context

    Initial coverage 6 months; continuation typically 12 months; prerequisite statin ± ezetimibe therapy required and documentation of LDL values within prior 120 days.

    Ustekinumab - GI/dermatology/rheum criteria

    Ustekinumab (Stelara) coverage criteria (examples):

    Crohn's Disease initial: (1) Diagnosis of moderately to severely active Crohn's disease; (2) Inadequate response or intolerance to TWO of the listed agents (eg, adalimumab, Skyrizi, Rinvoq, ustekinumab) OR documentation that trials are inappropriate; (3) Prescribed by or in consultation with a gastroenterologist.

    Coverage duration 12 months; reauthorization requires positive clinical response.

    Nuedexta - PBA criteria and exclusions

    Nuedexta (dextromethorphan/quinidine) exclusion and initial criteria:

    PBA initial: (1) Diagnosis of pseudobulbar affect (PBA) with an underlying neurologic condition (eg, ALS, MS, Alzheimer’s disease, Parkinson’s disease, stroke, traumatic brain injury); (2) Age ≥ 18 years; (3) No concomitant use of other drugs containing quinidine/quinine/mefloquine; (4) No history of severe reactions to quinidine/quinine/mefloquine; (5) Not taking MAOIs and no prolonged QT or interacting QT‑prolonging CYP2D6 substrates; (6) Prescribed by or in consultation with a neurologist or psychiatrist.

    Coverage duration 12 months; reauthorization requires documentation of clinical benefit.

    Olumiant - RA criteria

    Olumiant (baricitinib) coverage criteria (examples):

    RA initial: (1) Diagnosis of rheumatoid arthritis; (2) Inadequate response or intolerance to TWO of the following: adalimumab, Enbrel, Rinvoq, Xeljanz/Xeljanz XR, Orencia OR documentation that trials are inappropriate; (3) Prescribed by or in consultation with a rheumatologist.

    Coverage duration 12 months; concurrent biologic/JAK inhibitor or potent immunosuppressant therapy excluded.

    Exenatide - DM2 criteria

    Exenatide coverage criteria (type 2 diabetes mellitus):

    DM2 initial: (1) Documentation confirming type 2 diabetes mellitus (eg, A1C ≥ 6.5%, fasting plasma glucose ≥ 126 mg/dL, or 2‑hour plasma glucose ≥ 200 mg/dL on OGTT); (2) Inadequate response or intolerance to a minimum 90‑day supply of two preferred GLP‑1 receptor agonist brands (eg, Ozempic, Trulicity, Rybelsus, Mounjaro, liraglutide).A1C ≥6.5% or FPG ≥126 mg/dL or 2‑hr PG ≥200 mg/dL

    Coverage duration 12 months; reauthorization requires documentation of positive clinical response.

    Tavaborole - Onychomycosis criteria

    Tavaborole coverage criteria (onychomycosis):

    Onychomycosis initial: (1) Diagnosis of toenail onychomycosis due to Trichophyton rubrum or T. mentagrophytes confirmed by KOH, culture, or histology; (2) Condition causes functional debility or disruption of activities of daily living; (3) Inadequate response or intolerance to BOTH oral terbinafine and oral itraconazole OR topical ciclopirox.

    Coverage duration 1 year; prerequisite therapy required prior to approval.

    General PA criteria

    General acceptance for product PA:

    General PA acceptance: Approve when ANY of the following are met: (1) Drug is FDA‑approved for the requested indication and regimen; (2) Indication/regimen is NCCN Drugs & Biologics Compendium Category 1 or 2A; (3) Supportive narrative exists in AHFS‑DI or Clinical Pharmacology; (4) Micromedex provides supportive evidence; (5) Listed in Lexi‑Drugs with evidence level A; (6) Supported by peer‑reviewed medical literature.

    Applies to products listed under 'PA Criteria' in this section.

    PAH

    Pulmonary arterial hypertension (PAH) — initial and continuation criteria:

    PAH Initial: (1) Documentation of diagnosis of PAH WHO Group with NYHA Functional Class II–IV; (2) Diagnosis confirmed by right‑heart catheterization or echocardiography; (3) Hemodynamic documentation: mean PAP >20 mm Hg; PVR >2.0 WU; PCWP or LVEDP ≤15 mm Hg; (4) Prescribed by or in consultation with a cardiologist or pulmonologist.mean PAP >20 mm Hg; PVR >2.0 WU; PCWP/LVEDP ≤15 mm Hg

    Initial coverage typically 6 months.

    PAH Continuation: Stabilization or improvement as evaluated by a cardiologist or pulmonologist is required to continue therapy.

    Continuation coverage typically 12 months.

    Rheumatology biologics

    Rheumatologic biologic therapy (examples: Orencia):

    RA initial: (1) Diagnosis of rheumatoid arthritis; (2) Inadequate response or intolerance to at least one conventional DMARD (eg, methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine); (3) Prescribed by or in consultation with a rheumatologist.

    Coverage duration 12 months; reauthorization requires demonstration of positive clinical response.

    PsA/PJIA initial: (1) Diagnosis of psoriatic arthritis or polyarticular juvenile idiopathic arthritis; (2) Inadequate response or intolerance to required prior DMARD(s) as specified; (3) Specialist prescribing as applicable.

    Continuation requires documentation of clinical benefit.

    Lipid-lowering agents

    PCSK9 inhibitors and lipid-lowering agents (examples: Praluent, Repatha):

    HLA/ASCVD LDL requirement: ONE of the following: (A) LDL‑C ≥70 mg/dL after a minimum 8‑week trial of at least moderate‑intensity statin therapy at maximally tolerated dose, OR (B) documented statin intolerance per defined criteria (eg, rhabdomyolysis, CK >10× ULN, myalgia/myositis on two statins, hepatotoxicity).LDL‑C ≥70 mg/dL after statin trial

    Initial coverage commonly 6 months; continuation durations vary (examples up to 2 years) and require documented LDL‑C response.

    HoFH: Diagnosis of homozygous familial hypercholesterolemia with untreated LDL‑C >500 mg/dL or treated LDL‑C >300 mg/dL; member must be on other lipid‑lowering therapy and not using lomitapide concurrently.

    Continuation requires demonstration of LDL‑C reduction or positive clinical response.

    Hematology agents

    Eltrombopag/Promacta indications (ITP, aplastic anemia, hepatitis C–related thrombocytopenia):

    ITP initial: (1) Diagnosis of relapsed/refractory, persistent, or chronic immune thrombocytopenia (ITP); (2) Baseline platelet count <30,000/mcL; (3) Inadequate response or intolerance to one of corticosteroids, immune globulin, or splenectomy.platelets <30,000/mcL

    Coverage durations vary by indication (eg, ITP initial 12 months); reauthorization requires positive clinical response (platelet increase sufficient to avoid clinically important bleeding).

    First‑line severe aplastic anemia: Diagnosis of severe aplastic anemia meeting severity criteria and used in combination with standard immunosuppressive therapy when indicated.

    Coverage durations differ by indication (eg, first‑line severe aplastic anemia 6 months).

    Cystic fibrosis

    Cystic fibrosis (Orkambi):

    CF genotype requirement: Member is homozygous for the F508del mutation in the CFTR gene OR if genotype unknown, an FDA‑cleared CF mutation test confirms F508del on both alleles.

    Prescribed by or in consultation with a pulmonologist or CF care center specialist; coverage duration typically 12 months; reauthorization requires documented clinical response.

    Alpha-1 antitrypsin deficiency (chunk 90)

    Alpha-1 antitrypsin (AAT) deficiency — Covered when ALL of the following are met

    AAT initial coverage: (1) Medical records confirming congenital AAT deficiency by genotype (eg, PiZZ or other disease‑causing alleles) OR alleles associated with low serum AAT; (2) Clinical evidence of chronic emphysema without AAT‑associated liver disease; (3) Low serum AAT concentration as evidenced by defined laboratory thresholds (eg, <80 mg/dL by radial immunodiffusion; <50 mg/dL by nephelometry; <11 µM/L by nephelometry; <0.8 g/L).see node text

    Coverage duration: indefinite; prescribed and monitored per specialty guidance.

    Pulmonary arterial hypertension (chunks 95,108)

    Pulmonary arterial hypertension (PAH) — Covered when ALL of the following are met

    PAH initial coverage: (1) Diagnosis of PAH WHO Group with NYHA Functional Class II–IV; (2) Diagnosis confirmed by right‑heart catheterization or echocardiography; (3) Hemodynamic documentation: mean PAP >20 mm Hg; PVR >2.0 WU; PCWP or LVEDP ≤15 mm Hg; (4) For certain agents, prior inadequate response or intolerance to other PAH classes may be required per product‑specific rules.mean PAP >20 mm Hg; PVR >2.0 WU; PCWP/LVEDP ≤15 mm Hg

    Initial coverage often 6 months with continuation 12 months conditional on specialist‑documented stabilization or improvement.

    Hyponatremia (chunk 106)

    Hyponatremia — Covered when ALL of the following are met

    Hyponatremia coverage: (1) Diagnosis of clinically significant hypervolemic or euvolemic hyponatremia; (2) Serum sodium <125 mEq/L OR serum sodium 125–134 mEq/L with clinical symptoms (eg, nausea, vomiting, headache, lethargy, confusion); (3) Treatment initiated or re‑initiated in a hospital setting within the prior 30 days; (4) Inadequate response or intolerance to conservative measures (eg, fluid restriction, diuretics).serum sodium <125 mEq/L OR 125–134 mEq/L with symptoms

    Prescribed by or in consultation with cardiology/endocrinology/nephrology as specified; coverage duration 12 months.

    ANCA-associated vasculitis (chunk 102)

    ANCA-associated vasculitis (TAVNEOS) — Covered when ALL of the following are met

    ANCA-associated vasculitis coverage: (1) Diagnosis of severe active ANCA‑associated vasculitis (granulomatosis with polyangiitis [GPA] or microscopic polyangiitis [MPA]); (2) Use as an adjunct to standard therapy including glucocorticoids; (3) Concurrent immunosuppressant therapy with cyclophosphamide or rituximab is documented.

    Initial coverage 6 months; reauthorization requires sustained remission (eg, BVAS), reduction in glucocorticoid use, and ongoing immunosuppressant therapy; prescribed by or in consultation with nephrology, pulmonology, or rheumatology.

    Biologic/targeted therapy criteria (chunks 96,100,101,109)

    Autoimmune / inflammatory conditions treated with biologics (examples: psoriatic disease, RA, UC, AS, nr-axSpA)

    Biologic therapy coverage: Typical initial coverage requires: (1) Diagnosis of the specific autoimmune/inflammatory condition (eg, PsO, PsA, RA, UC, CD, AS, nr‑axSpA); (2) Documentation of inadequate response or intolerance to specified prior therapies (commonly two agents including TNF inhibitors, other biologics, or targeted synthetic DMARDs) OR documentation that trials are inappropriate; (3) Prescribed by or in consultation with the relevant specialist (eg, rheumatologist, dermatologist, gastroenterologist).

    Coverage duration commonly 12 months; reauthorization requires demonstration of positive clinical response; concurrent biologic DMARD therapy is generally excluded.

    Testosterone replacement criteria (chunk 104)

    Testosterone therapy — Covered when ALL of the following are met (selected items)

    Testosterone hypogonadism criteria: (1) For new starts: attestation that diagnosis of hypogonadism was confirmed by two early‑morning total testosterone measurements <300 ng/dL on separate occasions, with normal prolactin and presence of clinical signs or symptoms consistent with testosterone deficiency; (2) No active or untreated prostate or breast cancer OR, if history of prostate cancer, stability of disease per PSA and documented risk/benefit assessment; (3) Age requirements as specified per formulation.two early‑morning total testosterone <300 ng/dL

    Coverage duration often indefinite for appropriate indications; continuation requires ongoing monitoring and safety assessments (eg, PSA, hematocrit).

    Tetrabenazine criteria (chunk 105)

    Tetrabenazine and movement disorders

    Tetrabenazine coverage: Tardive Dyskinesia (TD) initial: (1) Diagnosis of TD; (2) Persistent symptoms despite dose reduction/tapering/discontinuation of offending agent OR member not a candidate for taper. Tourette's: inadequate response or intolerance to haloperidol or risperidone required prior to approval. Chorea of Huntington's disease: documented diagnosis required.

    TD initial coverage 3 months; reauthorization indefinite if positive clinical response documented; prescribed by or in consultation with neurology/psychiatry as appropriate.

    PAH (Initial and Continuation) — products listed in chunks 108 and 113

    Covered when ALL of the following are met:

    PAH initial diagnostic and functional criteria: (1) Documentation of PAH WHO Group with NYHA Functional Class II–IV; (2) Diagnosis confirmed by right‑heart catheterization or echocardiography; (3) Hemodynamic documentation including mean pulmonary arterial pressure >20 mm Hg, PVR >2.0 WU, and PCWP or LVEDP ≤15 mm Hg; (4) Prescribed by or in consultation with a cardiologist or pulmonologist.mean PAP >20 mm Hg; PVR >2.0 WU; PCWP/LVEDP ≤15 mm Hg

    Initial coverage 6 months; continuation 12 months with specialist documentation of stabilization or improvement.

    Psoriasis / Psoriatic Arthritis / Ulcerative Colitis / Crohn's Disease

    Covered when criteria specific to indication are met (examples below reflect the document):

    Psoriasis (PsO) initial: (1) Diagnosis of moderate to severe plaque psoriasis; (2) Inadequate response or intolerance to two of the listed systemic/biologic therapies (eg, Cosentyx, Enbrel, adalimumab, Skyrizi, ustekinumab, Otezla) OR documentation that trials are inappropriate.

    Prescribed by or in consultation with a dermatologist; coverage duration 12 months.

    Psoriatic Arthritis (PsA) initial: (1) Diagnosis of PsA; (2) Inadequate response or intolerance to two of the listed agents (eg, adalimumab, Enbrel, Cosentyx, Rinvoq, Skyrizi, ustekinumab, Xeljanz, Orencia, Otezla) OR documentation that trials are inappropriate.

    Prescribed by or in consultation with dermatologist or rheumatologist; coverage 12 months.

    Ulcerative Colitis (UC) initial: (1) Diagnosis of moderately to severely active UC; (2) Either: (A) Inadequate response or intolerance to two of the listed agents (eg, adalimumab, ustekinumab, upadacitinib, tofacitinib, risankizumab) OR documentation that trials are inappropriate; OR (B) Will be used as maintenance following IV induction dosing with the listed product.

    Prescribed by or in consultation with a gastroenterologist; coverage duration 12 months.

    Crohn's Disease (CD) initial: (1) Diagnosis of moderately to severely active CD; (2) Inadequate response or intolerance to two of the listed agents (eg, adalimumab, ustekinumab, Skyrizi, Rinvoq) OR documentation that trials are inappropriate; OR (B) Use as maintenance following IV induction dosing.

    Prescribed by or in consultation with a gastroenterologist; coverage 12 months.

    Cystic Fibrosis — Trikafta

    Covered when ALL of the following are met:

    CF Trikafta initial: (1) Diagnosis of cystic fibrosis; (2) Documentation of at least one F508del CFTR mutation detected by an FDA‑cleared CF mutation test OR if genotype unknown, an FDA‑cleared CF mutation test used to detect F508del on both alleles.

    Prescribed by or in consultation with a pulmonologist or CF care center specialist; coverage duration 12 months; reauthorization requires documented clinical benefit.

    Tymlos (Postmenopausal Osteoporosis / OSTm)

    Covered when ALL of the following are met:

    PMO initial: (1) Diagnosis of postmenopausal osteoporosis; (2) Severe osteoporosis or high/very high fracture risk defined by multiple vertebral fractures, BMD T‑score ≤ -2.5, or history of osteoporotic fracture; (3) Inadequate response or intolerance to one of bisphosphonates, hormone therapy, SERMs, or denosumab.

    Member age ≥18; initial coverage remainder of contract year; cumulative lifetime therapy limits may apply (eg, not to exceed 2 years on reauthorization for certain products).

    Tyvaso (PAH and PH-ILD)

    Covered when ALL of the following are met:

    Tyvaso PAH initial: PAH diagnostic and hemodynamic criteria as described for other PAH entries: mean PAP >20 mm Hg, PVR >2.0 WU, PCWP/LVEDP ≤15 mm Hg and NYHA Class II–IV, diagnosis confirmed by right‑heart catheterization or echocardiography.mean PAP >20 mm Hg; PVR >2.0 WU; PCWP/LVEDP ≤15 mm Hg

    Prescribed by or in consultation with cardiologist or pulmonologist; initial coverage 6 months; continuation 12 months with documented stabilization or improvement.

    Tyvaso PH‑ILD initial: (1) Diagnosis of pulmonary hypertension associated with interstitial lung disease (PH‑ILD, WHO Group 3); (2) Diagnostic confirmation by right‑heart catheterization, Doppler echocardiogram, or CT imaging as appropriate.

    Prescriber specialty and coverage durations align with PAH requirements; reauthorization requires specialist‑documented benefit.

    Veozah (VMS due to menopause)

    Covered when ALL of the following are met:

    VMS initial: (1) Diagnosis of moderate to severe vasomotor symptoms due to menopause; (2) Inadequate response or intolerance to one hormonal (eg, estradiol) or non‑hormonal therapy (eg, paroxetine, venlafaxine, clonidine); (3) Baseline liver tests with aminotransferases ≤2× ULN and total bilirubin ≤2× ULN.aminotransferases ≤2× ULN; total bilirubin ≤2× ULN

    Initial coverage 6 months; reauthorization 12 months with documented clinical response and absence of liver injury.

    Verquvo (Chronic Heart Failure)

    Covered when ALL of the following are met:

    CHF initial: (1) Diagnosis of chronic heart failure with NYHA Class II–IV; (2) Left ventricular ejection fraction <45%; (3) Either hospitalization for heart failure within prior 6 months OR outpatient IV diuretics within prior 3 months; (4) Inadequate response or intolerance to TWO of ACE inhibitor, ARB, ARNI, beta‑blocker, SGLT2 inhibitor, or MRA.EF <45%

    Prescribed by or in consultation with a cardiologist; coverage duration 12 months; reauthorization requires documentation of positive clinical response.

    Vowst (Prevention of rCDI)

    Covered when ALL of the following are met:

    Vowst initial: (1) Diagnosis of recurrent C. difficile infection (rCDI) with diarrhea (≥3 loose stools/24 hrs for ≥2 consecutive days) and positive stool test for C. difficile toxin or toxigenic C. difficile; (2) History of two or more recurrent CDI episodes within 12 months; (3) Completed at least 10 consecutive days of oral vancomycin or fidaxomicin within 2–4 weeks prior to administration; (4) Completed recommended bowel prep prior to administration; (5) Prior episode currently under control (eg, <3 unformed stools for ≥2 consecutive days).

    Member age ≥18; prescribed by or in consultation with gastroenterology or infectious disease specialist; coverage duration: single course 14 days.

    Vraylar (Bipolar Disorder, Schizophrenia, MDD adjunct)

    Covered when ALL of the following are met:

    BD initial: (1) Diagnosis of bipolar disorder; (2) Inadequate response or intolerance to two of the listed antipsychotics (eg, aripiprazole, quetiapine, asenapine, olanzapine, paliperidone, risperidone, ziprasidone).

    Coverage indefinite; approved for continuation when criteria met.

    Schizophrenia initial: (1) Diagnosis of schizophrenia; (2) Inadequate response or intolerance to two of the listed antipsychotics.

    Coverage indefinite; approved for continuation.

    MDD adjunct initial: (1) Diagnosis of major depressive disorder for adjunctive therapy; (2) Inadequate response or intolerance to aripiprazole and quetiapine.

    Coverage indefinite; approved for continuation.

    Trientine HCl (Wilson's disease)

    Covered when ALL of the following are met:

    Wilson's disease initial: (1) Diagnosis of Wilson's disease; (2) Inadequate response or intolerance to a penicillamine product.

    Prescribed by or in consultation with gastroenterology/hepatology or transplant specialist; coverage 12 months; reauthorization requires documented clinical response (eg, reduction in 24‑hour urinary copper).

    Voquezna (H. pylori and erosive esophagitis / GERD)

    Covered when criteria for indication are met:

    H. pylori: Use of Voquezna in combination with appropriate antibiotics for H. pylori eradication when indicated, including when prior therapy has failed or is contraindicated.

    Coverage durations differ by indication (eg, H. pylori 1 month; erosive esophagitis 8 weeks); prescribed per GI guidance.

    Erosive esophagitis (EE): (1) Use for healing of erosive esophagitis and symptom relief or maintenance of healing when there is inadequate response or intolerance to two generic PPIs.

    Coverage durations specified per indication.

    Xifaxan (HE prophylaxis, IBS-D, SIBO/SBBO)

    Covered when criteria for indication are met:

    HE prophylaxis: (1) Diagnosis of hepatic disease with risk for hepatic encephalopathy; (2) Inadequate response or intolerance to lactulose.

    Prescriber and documentation as specified; coverage per indication.

    IBS‑D: (1) Diagnosis of IBS‑D; (2) Inadequate response or intolerance to both a TCA or SSRI AND dicyclomine; (3) Member does not exceed total allowed courses and experiences IBS‑D symptoms.

    Reauthorization criteria apply for recurrence management.

    SBBO/SIBO initial: (1) Diagnosis of small bowel bacterial overgrowth (SBBO/SIBO); (2) Documentation as required per policy.

    Reauthorization requires documentation of recurrence following successful initial therapy.

    Xolair (Omalizumab) — Allergic Asthma, Chronic Urticaria, Nasal Polyps, IgE-Mediated Food Allergy

    Covered when indication-specific criteria are met:

    Moderate to severe persistent allergic asthma initial: (1) Diagnosis of moderate to severe persistent allergic asthma; (2) Positive skin test or in vitro reactivity to a perennial aeroallergen; (3) Baseline serum IgE within product‑required range (eg, 30–1300 IU/mL where specified); (4) Inadequate response or intolerance to high‑dose inhaled corticosteroid plus LABA.baseline IgE 30–1300 IU/mL where specified

    Prescribed by or in consultation with allergist/immunologist or pulmonologist; concurrent biologic therapy for asthma/allergic conditions is excluded.

    Chronic urticaria initial: (1) Diagnosis of chronic urticaria; (2) Inadequate response, contraindication, or intolerance to second‑generation H1 antihistamine at maximally tolerated dose plus adjunct options.

    Prescribed by or in consultation with allergist/immunologist or dermatologist.

    Nasal polyps initial: (1) Diagnosis of nasal polyps; (2) Use in conjunction with intranasal corticosteroid and inadequate response or intolerance to intranasal corticosteroid; (3) Baseline IgE level as applicable.

    Prescribed in consultation with allergy/immunology, pulmonology, or ENT; coverage typically 12 months.

    IgE‑Mediated Food Allergy (IMFA): (A) Diagnosis and clinical history of IgE‑mediated food allergy OR (B) history of severe allergic response/anaphylaxis to one or more foods; AND used in conjunction with food allergen avoidance; baseline (pre‑treatment) serum total IgE and body weight documented for dosing where required.baseline IgE per product guidance

    Subject to Part B vs Part D review where applicable; reauthorization requires documented clinical benefit and continued allergen avoidance.

    Sodium oxybate (Narcolepsy with cataplexy / EDSN)

    Covered when ALL of the following are met:

    Cataplexy initial: (1) Diagnosis of cataplexy with narcolepsy; (2) Diagnosis confirmed by polysomnography (PSG) or multiple sleep latency test (MSLT) or prescriber justification if testing not feasible; (3) No concurrent use of sedative hypnotics or alcohol; (4) Prescribed by or in consultation with a neurologist, psychiatrist, or sleep specialist.

    Coverage duration 12 months; reauthorization requires documentation of efficacy (eg, reduction in cataplexy frequency).

    EDSN initial: (1) Diagnosis of excessive daytime sleepiness in narcolepsy (EDSN, narcolepsy type 2); (2) Diagnosis confirmed by PSG or MSLT or prescriber justification if testing not feasible; (3) In adults, inadequate response or intolerance to modafinil or armodafinil prior to sodium oxybate; (4) Prescribed by or in consultation with a neurologist, psychiatrist, or sleep specialist.

    Coverage duration 12 months; reauthorization requires evidence of benefit and yearly reevaluation.

    IgE-Mediated Food Allergy (Initial)

    Covered when ALL of the following are met for IgE-mediated food allergy (IMFA) initial:

    IMFA initial: (1) Diagnosis of IgE‑mediated food allergy with supportive clinical history; (2) Documentation of history of severe allergic response including anaphylaxis to one or more foods; (3) Therapy used in conjunction with food allergen avoidance measures; (4) Baseline (pre‑treatment) serum total IgE and body weight documented for dosing calculations as required by product labeling.baseline IgE per product guidance

    Subject to Part B vs Part D review where applicable; reauthorization requires documentation of clinical benefit and continued allergen avoidance.

    IgE-Mediated Food Allergy (Reauthorization)

    Reauthorization requirements for IMFA:

    IMFA reauth: (1) Documentation of positive clinical response to therapy (eg, reduction in severity or frequency of allergic reactions, reduced need for rescue medications); (2) Continued use in conjunction with food allergen avoidance and periodic specialist re‑evaluation.

    Dosing remains weight‑ and IgE‑based per product labeling.

    Sodium oxybate (Initial)

    Covered when ALL of the following are met for sodium oxybate:

    Cataplexy initial: (1) Diagnosis of cataplexy with narcolepsy confirmed by PSG or MSLT or prescriber justification if testing is not feasible; (2) No concurrent use of sedative hypnotics or alcohol; (3) Prescribed by or in consultation with a neurologist, psychiatrist, or sleep specialist.

    Initial coverage 12 months; reauthorization requires documented efficacy and yearly re‑evaluation.

    EDSN initial: (1) Diagnosis of excessive daytime sleepiness in narcolepsy (EDSN); (2) Diagnosis confirmed by PSG or MSLT or justification if testing not feasible; (3) In adults, inadequate response or intolerance to modafinil or armodafinil prior to sodium oxybate; (4) Specialist prescribing as above.

    Coverage duration 12 months; reauthorization requires documented benefit.

    Sodium oxybate (Reauthorization)

    Reauthorization requirements for sodium oxybate:

    Sodium oxybate reauth: (1) Documentation supporting efficacy of the current regimen (eg, reduction in cataplexy attack frequency, improvement in Epworth Sleepiness Scale); (2) Member re‑evaluated at least annually by the prescribing specialist.

    Continued specialist involvement required; exclusion for concurrent sedative hypnotic or alcohol use.

    Miglustat (ZTALMY entry)

    Covered when ALL of the following are met for miglustat (Type 1 Gaucher's Disease):

    Miglustat initial: (1) Diagnosis of mild‑to‑moderate Type 1 Gaucher's Disease (T1GD); (2) Enzyme replacement therapy is not a therapeutic option due to allergy, hypersensitivity, or poor venous access; (3) Member is ≥18 years of age.

    Initial coverage 12 months; reauthorization requires documentation of positive clinical response.

    Concurrent-use exclusions are applied where coadministration would increase safety risk or duplicate mechanism. For pulmonary arterial hypertension (PAH) products the policy excludes concurrent use of phosphodiesterase inhibitors, nitrates, or nitric oxide donors and other soluble guanylate cyclase stimulators; pregnancy is also listed as an exclusion for some PAH agents. Requests with documented concomitant nitrate or PDE5 inhibitor use should be denied per the exclusion language and will risk noncoverage. (See PAH hemodynamic and diagnostic requirements when evaluating exceptions.)

    For agents where product labeling or the criteria specify, concurrent biologic disease-modifying antirheumatic drugs (DMARDs) or other tumor necrosis factor antagonists are explicitly excluded. Review the member’s medication list for overlapping biologic therapies; concurrent biologic therapy is a common exclusion across multiple rheumatologic and dermatologic biologic entries and may render therapy not medically necessary.

    When an exclusion is present in the criteria (e.g., concurrent nitrates with sildenafil/tadalafil or concurrent biologic DMARDs for specified biologics), lack of documentation that the exclusion does not apply (for example, evidence that the other drug was discontinued) may result in denial of the request.

    Concurrent use of another biologic disease-modifying antirheumatic drug (DMARD) or tumor necrosis factor antagonist is a standing exclusion for many biologic products covered under these criteria. Multiple biologic entries (PsA, PsO, AS, nr-axSpA, RA, PJIA and others) state that concurrent biologic DMARD therapy is not allowed and that approval requires failure or intolerance to specified prior therapies.

    Before approving a biologic, verify the medication history for active biologic agents; if the member is on another biologic the request should be denied per the exclusion unless clinical documentation demonstrates the concurrent use is medically appropriate and allowed by the specific product criteria (which is uncommon).

    Dalfampridine (AMPYRA) is excluded for members with a history of seizure disorder and for those with moderate to severe renal impairment. Specifically, the policy requires no history of seizure and a creatinine clearance > 50 mL/min (i.e., members with CrCL ≤ 50 mL/min are excluded). These safety-based exclusions must be confirmed from the medical record before approving therapy.

    Sodium phenylbutyrate and other UCD therapies exclude use in the setting of acute hyperammonemia. Additionally, N-acetyl glutamate synthase (NAGS) deficiency is listed as an exclusion for these products. Prior authorization requires confirmation of the chronic UCD diagnosis and that the request is not for acute emergency management.

    The policy excludes therapies intended for chronic management from use during episodes of acute hyperammonemia. For disorders such as NAGS deficiency the listed products are not appropriate; requests in the acute setting should be routed through urgent clinical review and are not approved under the chronic-treatment authorization criteria.

    Multiple biologic products include an explicit exclusion for coadministration with other biologic DMARDs (for example, TNF antagonists). When evaluating a biologic request, check for active prescriptions or recent administrations of other biologics; concurrent therapy typically meets exclusion criteria and is not permitted.

    Providers seeking combination biologic regimens must provide clear, indication‑specific justification aligned with the product criteria and supporting literature; absent such documentation, concurrent biologic use will be considered an exclusion and may lead to denial.

    Kineret (anakinra) and several other biologics specifically state that concurrent therapy with any other biologic DMARD (for example, TNF antagonists) is excluded. Prior authorization for Kineret requires verification that the member is not receiving another biologic DMARD and documentation of required prior therapies.

    Nuedexta (dextromethorphan/quinidine) carries exclusions based on drug interactions and cardiac risk: avoid use with other agents containing quinidine/quinine/mefloquine, in patients with a history of quinidine/quinine/mefloquine–induced serious adverse reactions, in those taking monoamine oxidase inhibitors within the prior 14 days, and in patients with prolonged QT, congenital long QT syndrome, or a history suggestive of torsades de pointes. Pregnancy and known hypersensitivity to dextromethorphan are also listed as exclusions.

    Quinine sulfate is excluded for the treatment or prevention of nocturnal leg cramps. If a request is submitted for this indication it should be denied per the stated exclusion.

    For certain plasma-derived or replacement products (example: alpha-1 antitrypsin entries), the policy lists IgA deficiency with known anti‑IgA antibody and active smoking as exclusions. Confirm relevant immunologic testing and smoking status when these products are requested; presence of these exclusions may preclude coverage.

    Concurrent biologic therapy exclusions are reiterated across multiple entries (see biologic/targeted therapy criteria). For immunologic and rheumatologic agents the policy consistently excludes simultaneous use of other biologic DMARDs or TNF antagonists; absence of documentation that concurrent biologic therapy has been discontinued will typically lead to denial.

    Tolvaptan (JYNARQUE) and other vasopressin receptor antagonists include several exclusions: members who are unable to sense or appropriately respond to thirst, those with hypovolemic hyponatremia, concurrent use of strong CYP3A inhibitors, anuria, and autosomal dominant polycystic kidney disease (ADPKD)–specific contraindications are noted. Confirm these clinical characteristics and concomitant medications prior to approval.

    Concurrent nitrate use is an exclusion for products in the phosphodiesterase inhibitor class and for tadalafil when used for BPH. The policy explicitly prohibits coadministration of nitrates with sildenafil/tadalafil preparations; verify nitrate prescriptions before approving these agents.

    Chunk 109 reiterates that concurrent therapy with biologic DMARDs or TNF antagonists is an exclusion for the listed products. For requests involving psoriasis, psoriatic arthritis, or related indications, confirm that the member is not receiving another biologic before approving therapy.

    For Xolair (omalizumab) and other asthma/allergy biologics, the policy excludes concurrent use of other biologic agents for asthma/allergic conditions (examples: benralizumab, dupilumab, mepolizumab). Review the member’s allergy/asthma biologic history and deny requests that would duplicate biologic therapy for allergic conditions.

    Sodium oxybate carries a firm exclusion against concurrent use of sedative hypnotics and alcohol. Requests must include documentation that the member is not using alcohol or sedative hypnotics concurrently; presence of these co‑exposures is grounds for denial.

    This sodium oxybate sedative/alcohol exclusion is restated in the sodium oxybate criteria: co‑administration with sedative hypnotics or alcohol is prohibited and may lead to denial if present. Prior authorization requires confirmation that the exclusion does not apply.

    Omalizumab (Xolair) is indicated for several allergic conditions but the policy specifies it is to be used in conjunction with food allergen avoidance for IgE‑mediated food allergy; it is not intended as a standalone substitute for avoidance strategies. Ensure an allergen‑avoidance plan is documented when authorizing Xolair for IMFA.

    CIMZIA and similar biologic entries reiterate the exclusion for concurrent biologic therapy; when assessing requests for biologics used in allergy or asthma, check for active prescriptions for other allergic‑disease biologics and deny if overlapping biologic therapy is present.

    When Xolair is requested for IMFA or allergic asthma, confirm baseline serum total IgE and body weight for dosing and that other biologic agents for the same allergic indication are not being used concurrently.

    Multiple entries are flagged as excluding concurrent biologic DMARDs; chunk references emphasize this is a widespread policy position across rheumatology and dermatology biologics. Lack of documentation that other biologics have been stopped will usually render the request not approvable under these criteria.

    Several products and portions of the policy are marked UNDER CMS REVIEW, indicating criteria or coverage specifics are pending. For those entries, coverage decisions may be limited or require additional review; check the policy section specific to the product for up-to-date determination and follow any stated interim requirements.

    Where a biologic or targeted therapy references exclusion for concurrent biologic DMARDs, that exclusion is part of the medical‑necessity logic and will generally render therapy not medically necessary if violated. Confirm prior-therapy history and active medications before approving continuation or new starts.

    The document contains multiple entries annotated as UNDER CMS REVIEW. These notes mean the criteria remain provisional pending CMS finalization; when an agent is so flagged, follow any interim guidance in the policy and be prepared to escalate to medical or pharmacy leadership for determination if coverage is uncertain.

    Some topical products have explicit cosmetic‑use exclusions. If the requested use is for cosmetic purposes rather than a medically accepted indication, mark the request not medically necessary per the cosmetic exclusion.

    Requests that lack documentation of required prior therapy or that are not prescribed by the required specialist may be deemed not medically necessary. Many biologic and specialty drug criteria require documented inadequate response/intolerance to specified prior agents and prescriber specialty consultation; absence of those elements should be documented as a reason for denial.

    Before denying for lack of prior therapy, ensure the requestor has had opportunity to demonstrate why trials were inappropriate or contraindicated; if such rationale is provided and clinically supported, reconsider per the product‑specific criteria.

    Initial Authorization / Initiation Requirements

    Reauthorization and Continuation Requirements

    Step Therapy Requirements and Prior-Therapy Trials

    RequirementDetails
    Step therapy requirementTrial of specified prior therapies is required prior to coverage unless documentation demonstrates trial is inappropriate (e.g., inadequate response or intolerance to listed agents).
    ApplicabilityApplies to multiple indications including rheumatologic, dermatologic, and GI biologic/JAK therapies as detailed in indication-specific criteria. Prescriber specialty and number/type of prior agents vary by indication.
    Documentation accepted in lieu of trialDocumentation that a trial is inappropriate (medical contraindication or intolerance) may be accepted instead of completing the required prior therapy trials.
    Examples of required prior agentsNotes
    AdalimumabFrequently listed as a required prior biologic across psoriasis, psoriatic arthritis, RA, Crohn's disease, and UC criteria. Trials of adalimumab are commonly required before approval of alternative biologics/JAK inhibitors.
    Ustekinumab (Stelara)Listed as a prior agent for Crohn's disease, UC, and psoriasis pathways in several biologic step therapy requirements.
    Risankizumab (Skyrizi)Included among alternatives in IBD and dermatology step therapy lists; inadequate response to risankizumab may be required prior to other therapies.
    Upadacitinib (Rinvoq)Listed as a prior or alternative agent for CD, UC, nr-axSpA and other inflammatory indications; trials of Rinvoq or Cosentyx required for some axial spondyloarthritis approvals.
    Tofacitinib (Xeljanz)Included in lists of prior therapies for ulcerative colitis and other immunologic indications where failure of multiple agents is required.
    Secukinumab (Cosentyx)Required or listed alternative for ankylosing spondylitis, nr-axSpA, and psoriasis step therapy pathways.
    ScenarioRequirement
    Rheumatologic/dermatologic biologics (e.g., Kineret, ILUMYA entries)Trial and failure (inadequate response or intolerance) of specified prior agents — commonly two biologic/TNF agents or specified DMARDs (may include methotrexate) — required before approval. Concurrent biologic therapy is excluded.
    Psoriasis / Psoriatic ArthritisInadequate response or intolerance to two listed systemic/biologic therapies (examples: Cosentyx, Enbrel, Adalimumab, Skyrizi, Ustekinumab) required prior to many biologic approvals.
    Ankylosing spondylitis / nr-axSpAInadequate response to two listed agents (eg, Adalimumab, Enbrel, Cosentyx) or to specific JAK inhibitors; for nr-axSpA, trial of an NSAID is also required.
    RequirementDetails
    Dietary management prerequisiteFor urea cycle disorders (UCD), inadequate response to dietary protein restriction or amino acid supplementation must be documented prior to pharmacologic therapy (e.g., sodium phenylbutyrate).
    Prescriber and testingDiagnosis must be confirmed by enzymatic, biochemical, or genetic testing and therapy prescribed by or in consultation with a metabolic disorders specialist. Initial authorization typically 6 months; reauthorization 12 months with documented clinical response.
    RequirementDetails
    GLP-1 step requirement prior to exenatideInadequate response or inability to tolerate a minimum 90-day supply of two preferred GLP-1 receptor agonist brands (examples listed: Ozempic, Trulicity, Rybelsus, Mounjaro, liraglutide) is required before exenatide approval for type 2 diabetes mellitus. Documentation of diagnosis (A1C or glucose criteria) is required.
    Documentation for reauthorizationReauthorization requires documentation of positive clinical response to therapy; coverage duration typically 12 months.
    RequirementDetails
    Statin and ezetimibe prerequisiteFor Nexletol/Nexlizet, members must have completed an adequate trial of statin therapy (≥8 weeks) at maximally tolerated dose OR documented statin intolerance, and at least 8–12 weeks of ezetimibe adjunctive therapy (or documented contraindication/intolerance to ezetimibe) prior to approval. LDL-C thresholds after statin therapy apply (examples provided in policy).
    LDL documentationLDL-C lab values within the last 120 days must meet specified thresholds (e.g., ≥55 mg/dL with ASCVD or other thresholds per indication); continuation requires demonstrated LDL reduction.
    RequirementDetails
    DMARD prerequisite for biologicsFor certain rheumatologic indications (e.g., Orencia), the member must have documented inadequate response or intolerance to at least one conventional DMARD (examples: methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine) before biologic therapy is approved. Prescriber specialty requirements apply. Coverage commonly 12 months.
    RequirementDetails
    Document prior therapies and inadequate responseFor hematology and other specialty agents (e.g., Promacta/eltrombopag), prior therapies such as corticosteroids, immune globulin, splenectomy, antithymocyte globulin/cyclosporine must be documented along with inadequate response before approval. Baseline labs (eg platelet counts) and prescriber specialty documentation are required.
    RequirementDetails
    Prior trials or documented inappropriatenessMany biologic/targeted therapy criteria require prior trials of listed agents (often two agents including TNF inhibitors, other biologics, or targeted therapies) or documentation that trials are inappropriate due to contraindication or intolerance. Prescriber specialty consultation is commonly required. Coverage durations commonly 12 months.
    ExamplesExamples across indications include requirement for trials of adalimumab, etanercept (Enbrel), secukinumab (Cosentyx), Skyrizi, ustekinumab, Rinvoq, Xeljanz, risankizumab, among others as specified per indication.
    RequirementDetails
    Document trials or contraindication/intolerance to alternativesBefore approval of many dermatologic, rheumatologic, GI, and neurologic specialty therapies, providers must document trials of listed alternative agents and either failure (inadequate response) or documented contraindication/intolerance. For sodium oxybate specifically, failure of listed agents is required (see sodium oxybate table).
    Sodium oxybate-specific prior therapyFor EDSN (narcolepsy type 2) in adults, inadequate response or intolerance to modafinil or armodafinil is required prior to sodium oxybate coverage. Cataplexy indication requires diagnostic confirmation (PSG/MSLT) and exclusion of concurrent sedative hypnotic/alcohol use.
    RequirementDetails
    Sodium oxybate prior therapy failureFailure (inadequate response) or intolerance to modafinil or armodafinil is required for adults with Excessive Daytime Sleepiness in Narcolepsy (EDSN) prior to coverage of sodium oxybate. Diagnostic confirmation by polysomnography (PSG) or MSLT is required or prescriber justification if testing is not feasible. Concurrent use of sedative hypnotics and alcohol is an exclusion. Coverage duration: 12 months; reauthorization requires documented efficacy and yearly re-evaluation.

    Prior Authorization, Documentation & Denial Risk Highlights

    Prior Authorization

    Prior authorization required

    Prior authorization is required for the drugs listed in this document; providers must submit the clinical information specified for the product (diagnosis, prior therapies, prescriber specialty, and coverage duration) when a drug shows "PA" in the Formulary Requirements column. Approvals follow the product-specific criteria provided in this policy.

    • Provide diagnosis and required supporting documentation as specified for the drug.
    • Document prior therapy trials or rationale why trials are inappropriate when required.
    • Ensure prescriber specialty/consultation is documented when the criteria require it.
    Prior Authorization

    Rinvoq for Crohn's Disease

    Rinvoq (upadacitinib) for moderate to severe Crohn’s disease requires prior authorization and documentation of inadequate response or intolerance to two of the following: adalimumab, ustekinumab, risankizumab, or upadacitinib (or documentation that a trial is inappropriate). The request must be prescribed by or in consultation with a gastroenterologist; coverage duration is typically 12 months.

    • Document trials of two specified biologics/JAK agents or provide reason trials are inappropriate.
    • Include gastroenterology consult/prescriber on the request.
    Prior Authorization

    Entyvio PA requirements

    Entyvio (vedolizumab) prior authorization for moderately to severely active UC or CD requires either failure/intolerance to two listed agents (e.g., adalimumab, ustekinumab, upadacitinib, tofacitinib, risankizumab) or use as maintenance following IV induction; prescribe by or in consultation with a gastroenterologist and document duration (12 months).

    • Provide documentation of two failed/ intolerant agents OR documentation of IV induction with Entyvio and plan for maintenance.
    • Document gastroenterology prescriber or consultation.
    Prior Authorization

    Enbrel PA requirements

    Enbrel (etanercept) prior authorization requires documentation of the indication and inadequate response or intolerance to the specified conventional DMARD(s) (e.g., methotrexate); prescriber must be or consult with the appropriate specialist (rheumatologist or dermatologist) and concurrent biologic DMARD therapy is excluded.

    • Document failed or intolerant conventional DMARD(s).
    • Do not combine with other biologic DMARDs; include specialist prescriber or consultation.
    Prior Authorization

    nr-axSpA PA requirements

    For non-radiographic axial spondyloarthritis (nr-axSpA), prior authorization requires inadequate response or intolerance to Rinvoq or Cosentyx (or documentation that a trial is inappropriate) and failure of at least one NSAID; document prior trials and prescriber specialty as required.

    • Document trial of Rinvoq or Cosentyx (or why trial inappropriate).
    • Document trial of at least one NSAID (ibuprofen, meloxicam, naproxen) or rationale.
    Prior Authorization

    Sodium phenylbutyrate PA

    Sodium phenylbutyrate for urea cycle disorders requires prior authorization with documentation of a confirmed UCD (enzymatic, biochemical, or genetic testing) and inadequate response to dietary protein restriction or amino acid supplementation; initial authorization is typically 6 months.

    • Include confirmatory testing for CPS, OTC, or ASS deficiency.
    • Provide documentation of dietary/dietary-supplement management and inadequate response.
    Prior Authorization

    UCD therapies PA

    Urea cycle disorder therapies require prior authorization: initial approvals are for 6 months and reauthorization for 12 months, with documentation of positive clinical response (e.g., plasma ammonia or amino acid levels) and concurrent dietary management.

    • Submit enzymatic/biochemical/genetic testing confirming UCD.
    • Provide laboratory monitoring and evidence of clinical response for reauthorization.
    Prior Authorization

    TOBI PODHALER PA

    TOBI PODHALER prior authorization requires a diagnosis of cystic fibrosis, evidence of Pseudomonas aeruginosa in the lungs, FEV1 between 25% and 75% predicted, and absence of Burkholderia cepacia colonization; prescriber should be a pulmonologist/CF specialist.

    • Provide microbiology showing P. aeruginosa and susceptibility where applicable.
    • Include recent FEV1 (25–75% predicted) and documentation excluding Burkholderia cepacia.
    Prior Authorization

    Kineret PA requirement

    Kineret (anakinra) requires prior authorization for indicated uses; providers must document the diagnosis and prerequisite therapy failures or intolerances as specified (e.g., for RA, inadequate response or intolerance to two specified prior therapies) and include specialist prescriber/consultation.

    • Document diagnosis and trials of required prior therapies (or rationale why trials are inappropriate).
    • Include rheumatology prescriber or consultation when indicated.
    Prior Authorization

    Exenatide PA requirement

    Exenatide prior authorization requires documentation confirming type 2 diabetes (chart notes or labs) and inadequate response or intolerance to a minimum 90-day supply of two preferred GLP‑1 receptor agonists (examples: Ozempic, Trulicity, Rybelsus, Mounjaro, liraglutide).

    • Provide A1C ≥6.5% or FPG ≥126 mg/dL (or OGTT criteria) to confirm diagnosis.
    • Document two 90-day trials of preferred GLP‑1 agents and reason for inadequate response or intolerance.
    Prior Authorization

    Nexletol/Nexlizet PA requirement

    Nexletol/Nexlizet prior authorization requires documentation of HeFH or primary hyperlipidemia and LDL‑C thresholds after at least an 8‑week trial of moderate‑intensity statin (or documented statin intolerance), plus adjunctive ezetimibe therapy (≥8–12 weeks) or documented contraindication; include current LDL‑C value.

    • Provide LDL‑C value from within the last 120 days and documentation of ≥8‑week statin trial or statin intolerance.
    • Document at least 8–12 weeks of ezetimibe use or reason ezetimibe is not appropriate.
    Note

    General PA acceptance criteria

    Approve prior authorization requests when any of the general acceptance criteria are met: FDA‑approved indication/regimen, NCCN Drugs & Biologics Compendium Category 1 or 2A, supportive AHFS/Clinical Pharmacology narrative, Micromedex support, Lexi‑Drugs evidence level A, or peer‑reviewed literature support.

    • Reference applicable supporting source(s) on the PA request.
    • If none apply, provide peer‑reviewed literature or other justification per policy.
    Prior Authorization

    PAH prior authorization

    PAH therapies require prior authorization with hemodynamic confirmation of PAH (mean PAP >20 mm Hg, PVR >2.0 WU, PCWP or LVEDP ≤15 mm Hg) documented by right‑heart catheterization or echocardiography; prescriber must be a cardiologist or pulmonologist; initial coverage is typically 6 months with continuation 12 months when stabilization or improvement is shown.

    • Attach right‑heart catheterization or echocardiography reports showing required hemodynamics.
    • Document WHO Group PAH diagnosis and NYHA Functional Class II–IV and specialist prescriber/consultation.
    Prior Authorization

    PCSK9 prior authorization

    PCSK9 inhibitor requests (e.g., Praluent, Repatha) require prior authorization documenting the diagnosis (HLA/ASCVD/HoFH), LDL‑C values after ≥8‑week moderate‑intensity statin trial (or statin intolerance), and other lipid‑lowering therapy as applicable; initial duration commonly 6 months.

    • Provide LDL‑C post‑statin value and documentation of statin trial or intolerance.
    • For HoFH include untreated/treated LDL thresholds and evidence of other lipid therapies.
    Prior Authorization

    RINVOQ cGVHD prior authorization

    RINVOQ (for chronic graft‑versus‑host disease) prior authorization requires diagnosis of cGVHD and inadequate response or intolerance to two or more systemic therapies; include that the request is prescribed by or in consultation with a hematologist/oncologist or transplant‑experienced physician; coverage is typically 12 months.

    • Document prior systemic therapy trials and dates, and current cGVHD status.
    • Include specialty prescriber or consultation and evidence of inadequate response.
    Prior Authorization

    SIGNIFOR prior authorization

    SIGNIFOR (pasireotide) prior authorization for pituitary Cushing’s disease requires documentation that pituitary surgery is not an option or was not curative and that treatment is prescribed by or in consultation with an endocrinologist; coverage duration is typically 12 months.

    • Provide surgical history and rationale why surgery is not an option or not curative.
    • Include endocrinology prescriber or consultation.
    Prior Authorization

    TRACLEER prior authorization

    Tracleer (bosentan) prior authorization for PAH requires documentation of PAH with hemodynamic confirmation and specialist prescribing; initial approval is typically 6 months with continuation 12 months contingent on demonstrated stabilization or improvement.

    • Attach diagnostic hemodynamics and specialist prescriber/consultation.
    • Document clinical response for reauthorization.
    Prior Authorization

    TAVNEOS prior authorization

    TAVNEOS prior authorization for severe active ANCA‑associated vasculitis requires diagnosis documentation, use as adjunct to standard therapy including glucocorticoids, and concurrent immunosuppressant therapy with cyclophosphamide or rituximab; initial approval typically 6 months.

    • Document BVAS or other disease activity measures and concurrent immunosuppressant use.
    • Include prescriber specialty (nephrology, pulmonology, or rheumatology) on the request.
    Prior Authorization

    PAH products PA requirement

    Prior authorization is required for PAH‑targeted products; initial approvals are commonly 6 months and continuation 12 months when diagnostic catheterization/echocardiography criteria and specialist oversight are documented.

    • Provide right‑heart catheterization or echo with required hemodynamics.
    • Confirm cardiology/pulmonology prescriber or consultation.
    Prior Authorization

    IBD products PA requirement

    Crohn’s disease and ulcerative colitis agents require prior authorization documenting inadequate response or intolerance to the specified biologics/JAK inhibitors (usually two agents) or documentation that induction IV therapy was given when Entyvio is being used as maintenance; include gastroenterology prescriber or consultation.

    • List prior biologic/JAK trials with dates and reasons for failure/intolerance.
    • If maintenance after IV induction, document induction dosing and timing.
    Prior Authorization

    IMFA (Xolair) prior authorization

    Omalizumab (Xolair) prior authorization for IgE‑mediated food allergy (IMFA) requires documentation of diagnosis and clinical history (including prior severe allergic response/anaphylaxis), baseline serum total IgE and body weight for dosing, and that therapy will be used in conjunction with food allergen avoidance.

    • Provide baseline serum total IgE and patient weight.
    • Document history of severe allergic reaction/anaphylaxis and food avoidance plan.
    Prior Authorization

    Sodium oxybate prior authorization

    Sodium oxybate prior authorization for cataplexy or excessive daytime sleepiness requires diagnostic confirmation by polysomnography (PSG) or multiple sleep latency testing (MSLT) or documented justification if testing is not feasible; for EDSN adults, document inadequate response or intolerance to modafinil or armodafinil prior to sodium oxybate.

    • Attach PSG or MSLT reports or prescriber justification if testing not feasible.
    • For EDSN in adults, include documentation of modafinil/armodafinil trial and failure or intolerance.
    Prior Authorization

    Miglustat (ZTALMY entry) prior authorization

    Miglustat (ZTALMY entry) prior authorization requires documentation of mild‑to‑moderate Type 1 Gaucher’s disease and that enzyme replacement therapy is not an option due to allergy, hypersensitivity, or poor venous access; member must be ≥18 years.

    • Provide diagnosis of T1GD and rationale why enzyme replacement therapy is not feasible.
    • Include age verification (≥18 years).
    Step Therapy

    Step therapy is used for some indications

    Step therapy is used for many indications: providers must document inadequate response or intolerance to the specified prior agents (often two agents or named alternatives) before the requested product will be approved, unless documentation shows trials are inappropriate.

    • List prior agents tried with dates, doses, and reason for failure or intolerance.
    • If trials are inappropriate, provide clinical justification.
    Step Therapy

    PJIA step therapy

    For polyarticular juvenile idiopathic arthritis (PJIA), initial therapy prior authorization requires inadequate response or intolerance to two agents (examples include Orencia or Rinvoq) or documentation that a trial is inappropriate; document prior agent trials and include rheumatology prescriber/consultation.

    • Provide documentation of two prior agent trials with dates and outcomes.
    • Include rheumatology prescriber or consultation.
    Step Therapy

    Biologic step therapy

    Many biologic agents require step therapy: prior inadequate response or intolerance to the specified prior agents (commonly two TNF/biologic agents or methotrexate where noted) must be documented before approval; concurrent biologic therapy is excluded.

    • Document prior biologic and DMARD trials with dates and reasons for failure.
    • Do not prescribe concurrently with other biologic DMARDs per exclusion.
    Step Therapy

    Exenatide step therapy

    Exenatide step therapy requires failure or inability to tolerate two preferred GLP‑1 receptor agonists, each for a minimum 90‑day supply, before exenatide will be approved; include documentation of those trials.

    • Document two 90‑day trials of preferred GLP‑1 agents and reasons for failure/intolerance.
    • Provide diabetes diagnostic evidence (A1C or fasting glucose) as specified.
    Step Therapy

    Nexletol/Nexlizet step requirements

    Nexletol/Nexlizet step requirements: document prior statin therapy and at least 8–12 weeks of ezetimibe (depending on product) prior to approval, and include LDL‑C values demonstrating thresholds as required.

    • Attach LDL‑C values after statin trial and ezetimibe trial duration.
    • Document statin intolerance if relevant.
    Step Therapy

    DMARD prerequisite for biologics

    For many rheumatologic biologics, providers must document prior DMARD trial/failure (e.g., methotrexate, hydroxychloroquine, leflunomide, azathioprine, sulfasalazine) before biologic therapy is authorized; include specialist prescriber/consultation.

    • List DMARD trials with doses and dates and reasons for inadequate response.
    • Include rheumatology prescriber or consultation.
    Step Therapy

    Therapy prerequisites for hematology agents

    Hematology agents (e.g., eltrombopag/Promacta) require documentation of prior therapies—such as corticosteroids, immune globulin, splenectomy—or other indicated treatments and baseline laboratory values (e.g., platelet counts) prior to authorization.

    • Provide baseline platelet count and prior therapy history with dates.
    • Document indication‑specific laboratory thresholds (e.g., platelet <30,000/mcL for ITP).
    Step Therapy

    REZDIFFRA step therapy

    REZDIFFRA (Rexulti entry) step therapy requires prior inadequate response or intolerance to specified alternative antipsychotics (schizophrenia: two agents; MDD adjunct: aripiprazole and quetiapine); document prior trials.

    • Provide names, durations, and outcomes of prior antipsychotic trials.
    • For MDD adjunct, document trials of aripiprazole and quetiapine.
    Step Therapy

    TALTZ step therapy

    TALTZ and related biologics require documented inadequate response or intolerance to specified biologics or DMARDs (usually two agents) for psoriasis, psoriatic arthritis, ankylosing spondylitis and nr‑axSpA prior to approval; include specialist prescriber/consultation.

    • Document prior biologic/DMARD trials (names, dates, reasons for failure).
    • Include dermatology or rheumatology prescriber/consultation as applicable.
    Step Therapy

    Prior biologic/JAK failures required

    Many immunologic and biologic agents require documented inadequate response or intolerance to prior biologic or JAK therapies (often two agents) before initial approval; providers must list prior biologic/JAK failures with dates and rationale.

    • List prior biologic and/or JAK inhibitor trials and objective evidence of inadequate response or intolerance.
    • If trials are inappropriate, include clear clinical justification.
    Step Therapy

    Step therapy for sodium oxybate

    For sodium oxybate (EDSN adults), prior authorization requires documentation of inadequate response or intolerance to modafinil or armodafinil before approval; for cataplexy and EDSN provide PSG/MSLT confirmation or prescriber justification if testing is not feasible.

    • Attach PSG/MSLT or prescriber justification if unavailable.
    • Document modafinil/armodafinil trial and failure for adult EDSN.
    Documentation Required

    When a drug has 'PA' in the Formulary Requirements column providers must follow criteria

    When a drug has "PA" in the Formulary Requirements column, providers must follow the criteria in this policy and supply required medical information such as diagnosis, prior therapies, prescriber consultation, and any specified supporting labs or test results.

    • Ensure all requested supporting documentation (labs, imaging, procedure reports) is included with the PA submission.
    • Use the product‑specific required medical information section in this document to confirm what to attach.
    Documentation Required

    Baseline labs for Epidiolex

    Epidiolex initiation requires baseline CBC, serum transaminases, and total bilirubin prior to starting therapy; requests should also document prior anticonvulsant trials and neurologist involvement.

    • Attach baseline CBC, AST/ALT, and total bilirubin results.
    • Document trial of at least one specified anticonvulsant (e.g., clobazam) and neurologist prescriber/consultation.
    Documentation Required

    Diagnostic confirmation and monitoring for UCD

    For UCD therapies (sodium phenylbutyrate), providers must document diagnostic confirmation by enzymatic, biochemical, or genetic testing and demonstrate inadequate response to dietary protein restriction or amino acid supplementation; reauthorization requires monitoring of plasma ammonia or amino acid levels and evidence of concomitant dietary management.

    • Include confirmatory enzymatic/biochemical/genetic test results.
    • Provide baseline and follow‑up plasma ammonia or amino acid levels for reauthorization and documentation of dietary measures.
    Documentation Required

    UCD required documentation

    For UCD initial requests include documentation of the diagnosis confirmed by enzymatic, biochemical, or genetic testing and that dietary protein restriction or amino acid supplementation was tried and found inadequate.

    • Attach testing confirming CPS/OTC/ASS deficiency.
    • Provide evidence of dietary management attempts and outcomes.
    Documentation Required

    Growth hormone required documentation

    Growth hormone therapy requests must include indication‑specific documentation such as height/height SDS, growth velocity, bone age, and abnormal provocative testing where required; prescriber should be an endocrinologist and reauthorization typically requires annual endocrinology re‑evaluation.

    • Provide height SDS, growth velocity data, bone age study, and provocative test results when applicable.
    • Include endocrinology prescriber/consultation and annual re‑evaluation documentation.
    Documentation Required

    JYNARQUE baseline labs

    JYNARQUE initiation requires baseline liver transaminases and bilirubin prior to starting therapy; include nephrology or transplant specialist prescriber/consultation documentation as required.

    • Attach baseline AST/ALT and total bilirubin labs.
    • Document prescriber specialty (nephrologist) and indication for ADPKD.
    Documentation Required

    Required clinical documentation (example)

    Provide required clinical documentation for products such as Kineret: for RA initial requests include diagnosis and documentation of inadequate response or intolerance to two specified prior therapies (examples listed) and rheumatology prescriber involvement.

    • List specific prior therapies tried with dates and outcomes.
    • Include rheumatology prescriber or consultation.
    Documentation Required

    Required clinical documentation for CMV

    For CMV treatment with Livtencity, include documentation of CMV diagnosis, transplant status, prior inadequate response to at least one prior therapy (e.g., oral valganciclovir), and pediatric weight/age criteria when applicable; prescriber should be a transplant/infectious disease/oncology specialist.

    • Provide transplant type/status and prior antiviral therapy documentation.
    • For pediatric members ≥12 years, include weight ≥35 kg if applicable.
    Documentation Required

    PAH required documentation

    PAH requests must include documentation of WHO Group PAH, NYHA Functional Class II–IV, and diagnostic confirmation by right‑heart catheterization or echocardiography with mean PAP, PVR, and PCWP/LVEDP values attached.

    • Attach right‑heart catheterization or echocardiography reports with hemodynamic values (mean PAP >20 mm Hg, PVR >2.0 WU, PCWP/LVEDP ≤15 mm Hg).
    • Document NYHA Functional Class and treating cardiologist/pulmonologist.
    Documentation Required

    Hyperlipidemia required documentation

    For hyperlipidemia/ASCVD PCSK9 requests, providers must supply diagnosis evidence and LDL‑C values obtained after ≥8 weeks of a moderate‑intensity statin (or documentation of statin intolerance) and any additional lipid‑lowering therapy information relevant to HoFH.

    • Provide LDL‑C result after ≥8‑week statin trial and documentation of statin intolerance if claimed.
    • Include information on other lipid‑lowering therapies used.
    Documentation Required

    Thrombocytopenia / aplastic anemia documentation

    For thrombocytopenia/aplastic anemia requests (e.g., eltrombopag/Promacta), include baseline platelet counts, prior therapy history (corticosteroids, IVIG, splenectomy), and laboratory criteria relevant to the indication.

    • Attach baseline platelet count and prior treatment documentation.
    • Document indication‑specific lab thresholds for reauthorization.
    Documentation Required

    CF genotype documentation

    For CF therapies such as Trikafta or Orkambi, providers must include documented CF diagnosis and CFTR genotype demonstrating at least one F508del mutation (or an FDA‑cleared CF mutation test when genotype is unknown); for inhaled antibiotics include FEV1 and microbiology evidence.

    • Attach CFTR genotype test results or FDA‑cleared mutation test.
    • Provide FEV1 values and microbiology evidence of Pseudomonas where applicable.
    Documentation Required

    AAT deficiency documentation

    For alpha‑1 antitrypsin (AAT) deficiency, include medical records confirming congenital AAT deficiency by genotype (e.g., PiZZ) and low serum AAT concentration (examples of thresholds are in the policy) plus clinical evidence of chronic emphysema.

    • Provide genotype documentation and serum AAT concentration (e.g., <80 mg/dL radial immunodiffusion or other listed thresholds).
    • Include clinical evidence of chronic emphysema without AAT‑related liver disease.
    Documentation Required

    PAH diagnostic confirmation required

    Right‑heart catheterization or echocardiography reports showing mean pulmonary arterial pressure, PVR, and pulmonary capillary wedge pressure/LVEDP must be attached to PAH requests to confirm hemodynamic criteria.

    • Attach the actual catheterization or echo report with numeric hemodynamic values.
    • If echo is used, include interpretation supporting PAH diagnosis.
    Documentation Required

    Hyponatremia documentation

    For hyponatremia (tolvaptan) requests, include serum sodium values meeting policy thresholds (<125 mEq/L or 125–134 mEq/L with symptoms), documentation that treatment was initiated or re‑initiated in a hospital within the past 30 days, and prior inadequate response to conservative measures.

    • Provide recent serum sodium measurements and documentation of hospital initiation if applicable.
    • Describe prior conservative measures tried and outcomes.
    Documentation Required

    PAH testing documentation

    For PAH testing documentation, attach the right‑heart catheterization or echocardiography report showing mean PAP, PVR and PCWP/LVEDP to support the diagnosis and meet hemodynamic thresholds required by policy.

    • Include numeric hemodynamic values and date of testing.
    • Document treating cardiologist/pulmonologist interpretation where available.
    Documentation Required

    Trikafta genotype documentation

    For Trikafta, provide CFTR genotype documentation showing at least one F508del mutation or an FDA‑cleared CF mutation test if genotype is unknown; include pulmonology/CF center prescriber information.

    • Attach CFTR genotype test report or FDA‑cleared mutation test.
    • Include prescriber specialty and clinical rationale.
    Documentation Required

    Vowst testing and prep documentation

    Vowst prior authorization requires documentation of at least two prior recurrent CDI episodes within 12 months, a positive stool test for C. difficile toxin or toxigenic C. difficile, completion of at least 10 days of oral vancomycin or fidaxomicin within 2–4 weeks prior, and completion of the recommended bowel prep before administration.

    • Attach stool toxin or toxigenic C. difficile test and records of prior CDI episodes.
    • Provide antibiotic treatment dates and bowel prep completion evidence.
    Documentation Required

    Required documentation for IMFA (initial)

    For Xolair IMFA initial requests, include diagnosis and clinical history of IgE‑mediated food allergy, documentation of prior severe allergic response (including anaphylaxis if present), baseline serum total IgE level, and body weight for dosing calculations.

    • Provide baseline serum total IgE and weight used to determine dosing.
    • Document history of severe allergic reactions and confirm therapy is used with allergen avoidance.
    Documentation Required

    Required documentation for sodium oxybate

    For sodium oxybate requests include diagnostic confirmation by PSG or MSLT (or prescriber justification if testing is not feasible); for EDSN adults, document inadequate response or intolerance to modafinil/armodafinil. Reauthorization requires evidence of efficacy and yearly reevaluation.

    • Attach PSG/MSLT or prescriber justification.
    • Document modafinil/armodafinil trial and the clinical response to sodium oxybate for reauth.
    Documentation Required

    Required documentation for miglustat

    For miglustat in Type 1 Gaucher’s disease, document diagnosis of mild‑to‑moderate T1GD and that enzyme replacement therapy is not an option due to allergy, hypersensitivity, or poor venous access; reauthorization requires documentation of positive clinical response.

    • Provide documentation that ERT is not feasible and that the patient meets T1GD diagnostic criteria.
    • Include objective evidence of clinical response for reauthorization.
    Denial Risk

    Failure to obtain prior authorization may result in plan not covering drug

    Failure to obtain prior authorization may result in the plan not covering the drug; providers should submit PA requests and required documentation before dispensing to avoid denial of coverage.

    • Submit PA prior to dispensing when "PA" is indicated on the Formulary.
    • If urgent, contact the plan per instructions in this document for assistance.
    Denial Risk

    Concurrent biologic therapy exclusion

    Concurrent therapy with other biologic DMARDs or tumor necrosis factor antagonists is an exclusion for many biologic products; prescribing a biologic concurrently with another biologic will likely result in denial.

    • Do not authorize or document concurrent biologic DMARD use for products that list this exclusion.
    • If clinically necessary, provide rationale why concurrent therapy is required and any supporting evidence.
    Denial Risk

    Seizure / renal impairment exclusion (dalfampridine)

    Dalfampridine is excluded for members with a history of seizure or moderate to severe renal impairment (CrCL ≤ 50 mL/min); ensure absence of these contraindications before requesting PA.

    • Document absence of seizure history and report current renal function (CrCL >50 mL/min).
    • Attach relevant neurology consult or labs if available.
    Denial Risk

    Urea Cycle Disorder documentation

    Requests for UCD therapies that lack confirmatory enzymatic, biochemical, or genetic testing for CPS/OTC/ASS deficiencies or that fail to document inadequate response to dietary measures risk denial.

    • Attach confirmatory testing results and documentation of dietary interventions tried.
    • Provide plasma ammonia or amino acid levels when available.
    Denial Risk

    Cystic Fibrosis eligibility for TOBI PODHALER

    TOBI PODHALER requests without evidence of Pseudomonas aeruginosa in the lungs, without FEV1 between 25%–75% predicted, or with Burkholderia cepacia colonization may be denied; include microbiology and spirometry data.

    • Provide microbiology confirming P. aeruginosa and FEV1 values.
    • Document absence of Burkholderia cepacia colonization.
    Denial Risk

    Immune globulin documentation

    Immune globulin therapy requests missing diagnosis‑specific criteria (e.g., inadequate response to conventional therapy, platelet thresholds, IgG levels) may be denied; include indication‑specific lab values and prior treatment history.

    • Attach baseline IgG or platelet counts and prior therapy documentation.
    • Provide specialty prescriber consultation when indicated (hematology, immunology).
    Denial Risk

    Concurrent biologic therapy exclusion (Kineret)

    Some biologics (e.g., Kineret) exclude concurrent therapy with any other biologic DMARD; requests that include concurrent biologics risk denial unless a clear, documented exception applies.

    • Do not list concurrent biologic DMARDs on the PA request for affected products.
    • If concurrent therapy is claimed to be necessary, provide detailed clinical justification.
    Denial Risk

    Concurrent immunosuppressive therapy exclusion

    Concurrent use of other biologic DMARDs, JAK inhibitors, or potent immunosuppressants (e.g., azathioprine, cyclosporine) is an exclusion for certain products (e.g., Olumiant); document that such concurrent immunosuppression is not being used.

    • State clearly on the request whether concurrent immunosuppressants are being used.
    • If concurrent immunosuppression is present, provide justification per policy.
    Denial Risk

    PAH diagnostic confirmation

    Lack of documentation confirming PAH diagnosis by right‑heart catheterization or echocardiography (including mean PAP >20 mm Hg, PVR >2.0 WU, and PCWP/LVEDP ≤15 mm Hg) may lead to denial of PAH therapy requests.

    • Attach catheterization/echo reports with numeric hemodynamics.
    • Document WHO Group PAH and NYHA Functional Class II–IV.
    Denial Risk

    LDL-C / statin trial documentation

    For lipid‑lowering therapies, absence of documented LDL‑C thresholds after an adequate trial of moderate‑intensity statin (minimum 8 weeks) or missing evidence of statin intolerance may trigger denial.

    • Provide LDL‑C values after ≥8 weeks of statin therapy.
    • If statin intolerance is claimed, include documentation per policy definitions.
    Denial Risk

    REPLACED/REXULTI (chunk 90)

    REPLACED/REXULTI product exclusions: requests for the product in chunk 90 may be denied if the member has IgA deficiency with known anti‑IgA antibody or is an active smoker; confirm these conditions are absent.

    • Document IgA status and smoking status in the medical record.
    • If either condition exists, provide clinical rationale if requesting an exception.
    Denial Risk

    sildenafil (chunk 95)

    Sildenafil products (for PAH or Raynaud’s Phenomenon) exclude concurrent nitrate use; providers must confirm the member is not taking nitrates to avoid denial.

    • Document current medications and explicitly confirm absence of nitrates.
    • If nitrates are necessary, explain clinical justification (note: policy exclusion applies).
    Denial Risk

    tadalafil (chunk 99)

    Tadalafil products used for BPH exclude concurrent nitrates; document medication list to confirm no nitrate use before requesting PA for tadalafil in BPH.

    • Provide current medication list and state no nitrates are being used.
    • If nitrates are present, include clinical rationale (may not meet policy criteria).
    Denial Risk

    Biologic DMARD concurrency exclusions (chunks 96,109)

    Concurrent use of other biologic DMARDs or TNF antagonists is an exclusion for multiple agents (chunks 96,109); documenting concurrent biologic therapy will generally result in denial unless policy allows an exception.

    • Do not request concurrent biologic DMARD therapy for excluded products.
    • If concurrent therapy is clinically necessary, provide detailed justification and supporting evidence.
    Denial Risk

    PAH diagnostic confirmation required

    PAH therapies require diagnostic confirmation by right‑heart catheterization or echocardiography with hemodynamic parameters (mean PAP >20 mm Hg, PVR >2.0 WU, PCWP/LVEDP ≤15 mm Hg); lack of these data may trigger denial.

    • Attach diagnostic hemodynamic testing reports with numeric values.
    • Document specialist prescriber involvement and functional class.
    Denial Risk

    Vowst prerequisites

    Vowst requests lacking documentation of at least two prior recurrent CDI episodes within 12 months, a positive stool test for C. difficile toxin, completion of the required antibiotic course (vancomycin or fidaxomicin), and bowel prep may be denied.

    • Provide stool toxin test and history of two or more recurrent CDI episodes within 12 months.
    • Attach records showing completion of the indicated antibiotic course and bowel prep.
    Denial Risk

    Xolair concurrent biologic exclusion

    Xolair (omalizumab) excludes concurrent use of other biologic agents for asthma/allergic conditions (e.g., benralizumab, dupilumab, mepolizumab); requests documenting concurrent biologics may be denied.

    • Confirm no concurrent biologic therapy for asthma/allergic conditions when requesting Xolair.
    • If concurrent therapy exists, provide detailed clinical justification.
    Denial Risk

    Sodium oxybate exclusion that may trigger denial

    Concurrent use of sedative hypnotics and alcohol is an exclusion for sodium oxybate and may trigger denial; confirm absence of sedative hypnotic use and counsel patients accordingly.

    • Document medication list (sedative hypnotics) and alcohol use status.
    • If present, provide justification for exception (policy exclusion applies).

    Codes, Clinical Thresholds and Key Values

    Covered products (excerpted names)NDC/mixedCovered
    KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGEProduct listed for PA
    Oncology and specialty products (partial list)mixedCovered
    abiraterone acetateProduct listed
    imatinib mesylate oralProduct listed
    everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5Product listed
    No explicit CPT/HCPCS/ICD-10/NDC codes presentmixed
    No codes listed
    Pulmonary hemodynamics (PAH thresholds)
    Mean pulmonary arterial pressure (mPAP)> 20 mm Hg
    Pulmonary vascular resistance (PVR)> 2.0 Wood Units (WU)
    Pulmonary capillary wedge pressure (PCWP) / LVEDP≤ 15 mm Hg
    Cystic fibrosis FEV1
    FEV1 (Cystic fibrosis — CAYSTON)25% to 75% of predicted
    Evidence requirementDocumented Pseudomonas aeruginosa in the lungs and susceptibility to aztreonam
    ExclusionNot colonized with Burkholderia cepacia
    FEV1 range
    FEV1 range (policy references)25% - 75% of predicted
    ContextUsed for eligibility for inhaled tobramycin/aztreonam in CF
    MonitoringReauthorization requires evidence of clinical response (improved FEV1)
    Height SDS for ISS
    Height SDS threshold for ISS≤ -2.25 (height standard deviation score)
    Use caseEligibility for Idiopathic Short Stature (ISS) GH therapy
    DocumentationHeight SDS must be documented using age- and gender-specific growth charts
    High dose opioid morphine equivalent
    High-dose opioid threshold (MED)≥ 90 mg morphine equivalent dose (MED) per day
    Continuation criteriaFor continuing high-dose opioid therapy: documented pain assessment within 6 months and clinically meaningful improvement
    Exclusions/requirementsMember must not be treated for substance abuse; subject to additional review for ESRD-related use
    LDL-C thresholds
    LDL‑C threshold with ASCVD>= 55 mg/dL (within last 120 days) for members with ASCVD
    LDL‑C threshold without ASCVD>= 100 mg/dL (within last 120 days) for members without ASCVD
    Statin trial requirementLDL thresholds evaluated after ≥8‑week trial of at least moderate‑intensity statin or documented statin intolerance
    Livtencity pediatric weight threshold
    Pediatric weight threshold (Livtencity)>= 35 kg for pediatric members (age ≥ 12 years)
    Age requirementMember must be ≥12 years of age
    PrescriberPrescribed by or in consultation with transplant/infectious disease/oncology specialist
    Mean pulmonary arterial pressure threshold
    Mean pulmonary arterial pressure (mPAP)> 20 mm Hg
    ContextRequired hemodynamic criterion for PAH diagnosis confirmed by catheterization or echocardiography
    Coverage timingDocumented for initial PA approvals (initial 6 months; continuation 12 months)
    Pulmonary vascular resistance threshold
    Pulmonary vascular resistance (PVR)> 2.0 Wood Units (WU)
    Measurement methodReported from right‑heart catheterization; echocardiography may suggest elevation but catheterization preferred
    Use in criteriaPart of required hemodynamic confirmation for PAH initial approval
    Baseline platelet count for ITP
    Baseline platelet count for ITP< 30,000/mcL
    DocumentationBaseline platelet count must be provided prior to eltrombopag/Promacta initiation
    Prior therapyInadequate response or intolerance to one of corticosteroids, IVIG, or splenectomy required
    LDL-C threshold for HLA/ASCVD
    LDL‑C threshold for HLA/ASCVD after statin trial>= 70 mg/dL after ≥8‑week trial of at least moderate‑intensity statin therapy
    Statin intolerance definitionDocumented rhabdomyolysis, CK >10× ULN, myalgia/myositis on two statins, or hepatotoxicity (AST/ALT >3× ULN)
    ContextApplies to PCSK9 inhibitor prior authorization (HLA/ASCVD pathway)
    Untreated LDL-C for HoFH
    Untreated LDL‑C for HoFH> 500 mg/dL
    RequirementDiagnosis of homozygous familial hypercholesterolemia required; member must be on other lipid‑lowering therapy
    Combination exclusionNot used in combination with lomitapide (Juxtapid)
    Treated LDL-C for HoFH
    Treated LDL‑C for HoFH> 300 mg/dL while on treatment
    ContextApplies when evaluating eligibility for PCSK9 or other advanced lipid therapies in HoFH
    ContinuationRequires demonstration of positive clinical response (LDL‑C reduction)
    AAT serum concentration thresholds
    AAT serum concentration examples< 80 mg/dL (radial immunodiffusion); < 50 mg/dL (nephelometry); < 11 µM/L (nephelometry); < 0.8 g/L
    Diagnostic confirmationGenotype confirmation (e.g., PiZZ or other disease‑causing alleles) plus low serum AAT and clinical emphysema
    Coverage stanceIndefinite coverage when criteria met
    PAH hemodynamic thresholds
    PAH hemodynamic thresholdsMean PAP >20 mm Hg; PVR >2.0 WU; PCWP/LVEDP ≤15 mm Hg
    ConfirmationRequired by right‑heart catheterization or echocardiography per policy
    PrescriberPrescribed by or in consultation with a cardiologist or pulmonologist; initial coverage 6 months
    Hyponatremia serum sodium thresholds
    Hyponatremia serum sodium (severe)< 125 mEq/L
    Hyponatremia (symptomatic/mild)125 - 134 mEq/L with symptoms (nausea, vomiting, headache, lethargy, confusion)
    Treatment contextTreatment initiated or re‑initiated in hospital within past 30 days and inadequate response to conservative measures required
    Testosterone total level threshold for hypogonadism
    Testosterone total level thresholdTwo early morning total testosterone levels < 300 ng/dL on separate occasions
    Additional requirementsNormal prolactin and presence of physical or cognitive symptoms consistent with testosterone deficiency
    Age limitsMember ≥12 years for generic testosterone cypionate (others ≥18 years as specified)
    Mean pulmonary arterial pressure (duplicate threshold reference)
    Mean pulmonary arterial pressure (duplicate)> 20 mm Hg
    NoteRepeated as core diagnostic PAH criterion across multiple product entries
    MeasurementDocumented by right‑heart catheterization or echocardiography per policy
    Pulmonary vascular resistance (PVR)
    Pulmonary vascular resistance (PVR) (duplicate)> 2.0 Woods Units
    Used forHemodynamic confirmation of PAH required for prior authorization
    SourceRight‑heart catheterization preferred; echoed across PAH product criteria
    Pulmonary capillary wedge pressure or LVEDP
    Pulmonary capillary wedge pressure / LVEDP≤ 15 mm Hg
    SignificanceUsed to distinguish pre‑capillary PAH (PCWP/LVEDP ≤15 mm Hg) as part of diagnostic hemodynamics
    DocumentationReported from right‑heart catheterization; required for PAH prior authorization
    Baseline serum total IgE (Xolair requirement referenced)
    Baseline serum total IgE (Xolair/IMFA)Baseline (pre‑treatment) serum total IgE level is required for dosing and eligibility (exact numeric threshold referenced in full policy)
    UseRequired for IgE‑mediated food allergy dosing and for other Xolair indications (as applicable)
    Dosing considerationsDosing is based on body weight and baseline serum total IgE

    Site-of-Care and Initiation Setting Notes

    Note

    Infusion / specialist oversight

    Infusion‑capable or specialist‑supervised settings are expected for many specialty therapies; PAH therapies in particular require specialist oversight though site restrictions are not explicitly limited in the excerpt.

    • Prescriber specialty required (cardiologist/pulmonologist)
    Note

    Hospital outpatient / recent inpatient initiation

    Some therapies require initiation in or shortly after a hospital stay (e.g., tolvaptan requires treatment initiated or re‑initiated in hospital within the past 30 days), so providers should document recent inpatient initiation when applicable.

    • Prescriber: cardiologist, endocrinologist, or nephrologist for hyponatremia/tolvaptan

    Background and Scope

    This section of the AmeriHealth Medicare PPO drug criteria provides utilization management rules for a broad set of specialty and non‑specialty drugs. It summarizes that many agents require prior authorization, often mandate trials of specified prior therapies (step therapy), and include prescriber specialty and documentation requirements such as diagnostic confirmation and baseline labs.

    The policy consistently requires hemodynamic confirmation and specialist involvement for pulmonary arterial hypertension (PAH) therapies (diagnostic thresholds include mean pulmonary arterial pressure > 20 mm Hg, pulmonary vascular resistance > 2.0 Wood Units, and pulmonary capillary wedge pressure or LVEDP ≤ 15 mm Hg), and sets initial and continuation coverage durations (commonly initial 6 months, continuation 12 months) tied to documented stabilization or improvement.

    Overall, these criteria are designed to ensure therapies are used in appropriate clinical contexts with documented prior therapies, specialist oversight, and safety monitoring; failure to meet listed prerequisites or presence of exclusions (for example, concurrent biologic use, seizure history for dalfampridine, or sedative/alcohol co‑use with sodium oxybate) may result in denial.

    Definitions and Diagnostic Criteria

    PAH diagnostic confirmation
    PAH diagnostic confirmationDiagnosis confirmed by right‑heart catheterization or echocardiography with mPAP >20 mm Hg, PVR >2.0 WU, and PCWP/LVEDP ≤15 mm Hg
    Functional classNYHA/WHO Functional Class II–IV required in PAH entries
    PrescriberPrescribed by or in consultation with a cardiologist or pulmonologist; initial coverage typically 6 months
    Urea Cycle Disorder (UCD)
    Urea Cycle Disorder (UCD) definitionDisorder involving deficiencies of CPS, OTC, or ASS confirmed by enzymatic, biochemical, or genetic testing
    Treatment contextPharmacologic therapy (eg sodium phenylbutyrate) requires inadequate response to dietary protein restriction or amino acid supplementation
    PrescriberPrescribed by or in consultation with a metabolic disorders specialist
    DS/LGS/TSC (Epidiolex indications)
    DS / LGS / TSC (Epidiolex) definitionsIndications include Dravet Syndrome, Lennox‑Gastaut Syndrome, Tuberous Sclerosis Complex; baseline CBC, serum transaminases and total bilirubin required prior to initiation
    Prior therapyInadequate response or intolerance to specified anticonvulsant(s) required
    PrescriberPrescribed by or in consultation with a neurologist
    Growth Failure in Children (GFC)
    Growth Failure in Children (GFC) definitionGrowth failure characterized by height or growth velocity ≤ specified SD thresholds, delayed bone age, and abnormal provocative testing as detailed for GH therapy
    DocumentationMay include height/SDS, growth velocity, bone age, and provocative testing results
    PrescriberPrescribed by or in consultation with an endocrinologist
    Urea Cycle Disorder (duplicate definition)
    UCD (duplicate definition)Deficiencies of CPS, OTC, or ASS confirmed by enzymatic, biochemical, or genetic testing; requires dietary management prior to pharmacologic therapy
    ReauthRequires documentation of positive clinical response and continued dietary restriction
    Coverage durationsInitial 6 months; reauthorization 12 months
    NOMID / NLRP3 mutation
    NOMID / NLRP3 mutation definitionNeonatal‑Onset Multisystem Inflammatory Disease may be confirmed by NLRP3 gene mutation or evidence of active inflammation
    PrescriberPrescribed by or in consultation with a rheumatologist or pediatric specialist
    CoverageTypically 12 months with reauth requiring positive clinical response
    Pseudobulbar affect (PBA)
    Pseudobulbar affect (PBA) definitionDiagnosis of PBA in context of underlying neurologic conditions (ALS, MS, Alzheimer’s, Parkinson’s, stroke, TBI); therapy limited to adults
    PrescriberPrescribed by or in consultation with neurologist or psychiatrist
    ExclusionsMultiple drug interactions and cardiac contraindications (eg prolonged QT) noted for Nuedexta
    Pulmonary arterial hypertension (PAH) diagnostic criteria
    PAH diagnostic criteria (concise)mPAP >20 mm Hg; PVR >2.0 WU; PCWP/LVEDP ≤15 mm Hg; NYHA/WHO FC II–IV; confirmed by catheterization or echocardiography
    DocumentationRight‑heart catheterization or echocardiography reports must show required hemodynamics
    Specialist involvementDiagnosis and ongoing management by cardiologist or pulmonologist required for PAH therapies
    Statin intolerance
    Statin intolerance definitionDocumented rhabdomyolysis or CK >10× ULN; myalgia/myositis with two statins; hepatotoxicity (AST/ALT >3× ULN) or significant liver disease
    UseAcceptable documentation to qualify for alternative lipid therapies when statin intolerance present
    ContextApplies to PCSK9 and other lipid‑lowering agent prior authorization pathways
    Alpha-1 antitrypsin (AAT) deficiency criteria
    Alpha‑1 antitrypsin (AAT) deficiency criteriaGenotype confirmation (eg PiZZ or disease‑causing alleles) plus low serum AAT (eg <80 mg/dL radial immunodiffusion; <50 mg/dL nephelometry; <11 µM/L)
    Clinical requirementClinical evidence of chronic emphysema without AAT‑associated liver disease
    CoverageIndefinite when criteria met
    Pulmonary arterial hypertension (PAH) diagnostic hemodynamics
    PAH diagnostic hemodynamics (definition)mPAP >20 mm Hg; PVR >2.0 WU; PCWP/LVEDP ≤15 mm Hg
    Confirmation methodRight‑heart catheterization preferred; echocardiography acceptable for suggestive findings but hemodynamics required
    Functional requirementNYHA/WHO Functional Class II–IV included in diagnostic criteria
    Pulmonary arterial hypertension (PAH)
    PAH definition (succinct)mPAP >20 mm Hg; PVR >2.0 WU; PCWP/LVEDP ≤15 mm Hg; WHO Group with NYHA FC II–IV; confirmed by catheterization/echocardiography
    Treatment oversightPrescribed by cardiologist or pulmonologist; initial coverage 6 months, continuation 12 months
    ReauthorizationRequires stabilization or improvement per specialist assessment
    Recurrent C. difficile infection (rCDI)
    Recurrent C. difficile infection (rCDI) definitionDiarrhea (≥3 loose stools/24 hrs for ≥2 consecutive days) plus positive stool test for C. difficile toxin or toxigenic C. difficile and history of ≥2 recurrent CDI episodes within 12 months
    Pre‑treatment requirementsCompletion of recommended bowel prep and recent appropriate antibiotic therapy prior to Vowst
    PrescriberPrescribed by or in consultation with gastroenterologist or infectious disease specialist
    IMFA
    IMFA (IgE‑Mediated Food Allergy) definitionRequires diagnosis and clinical history of IgE‑mediated food allergy or history of severe allergic response/anaphylaxis; used with allergen avoidance
    Baseline labsBaseline (pre‑treatment) serum total IgE level and body weight required for dosing of omalizumab
    ReauthorizationRequires documentation of positive clinical response and continued allergen avoidance
    EDSN
    EDSN (Excessive Daytime Sleepiness in Narcolepsy) definitionDiagnosis typically confirmed by polysomnography (PSG) or multiple sleep latency test (MSLT); adult EDSN requires inadequate response to modafinil/armodafinil prior to sodium oxybate
    PrescriberPrescribed by or in consultation with neurologist, psychiatrist, or sleep specialist
    ExclusionConcurrent use of sedative hypnotics and alcohol is contraindicated for sodium oxybate